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3Measure what is measurable and make measurable
what cannot now be measured.
-Galileo
4ABSTRACT
Toxic and incapacitating chemicals are ubiquitous in everyday life. Despite the prohibition of
chemical weapons by the Chemical Weapons Convention (CWC), many chemicals are still
used: as legal riot control agents, in various processes and products of the chemical industry
or as pesticides in agriculture. Validated analytical methods and knowledge of toxicology
and metabolism are therefore needed for the verification of possible intentional or
unintentional exposures in carrying out occupational tasks or in civil incidents.
The most reliable retrospective detection and confirmation of exposure to chemicals are
achieved by analyzing unequivocal metabolites such as biomarkers, from biological samples,
which have mainly been obtained from exposed persons, animals and experimental animal
models. However, the use of animal testing for evaluating the safety and effects of chemicals
that are known to be toxic or incapacitating raises ethical questions. Therefore, the use of an
in vitro metabolism study approach to predict in vivo metabolite profiles, prior to obtaining
more detailed knowledge in vivo could be a preferable strategy for evaluating the toxicology
of these chemicals.
In the series of five studies presented in this thesis, four toxic and incapacitating
chemicals listed in the CWC or used for riot control were studied, namely: sulfur mustard,
capsaicinoids, chloropicrin and saxitoxin. Each of these studied chemicals has different
chemical properties and toxicological mechanisms. The suitability of the conventional in
vitro metabolism studies were assessed in this research. These assessments were achieved by
using various mass spectrometric (MS) methods to screen and identify the formed
metabolites and compare them to previous findings. The validations of analyses methods for
known biomarkers were carried out according to the current bioanalytical validation
guidelines and identification criteria, which were evaluated to avoid false positive results.
In vitro metabolism studies in this thesis used mainly human and pig liver cell fractions.
Metabolites of sulfur mustard and capsaicinoids were screened by liquid chromatography−
tandem mass spectrometry (LC−MS/MS). Parent ion scans, product ion scans (MS/MS,
MS3) and accurate mass measurements using liquid chromatography−time-of-flight mass
spectrometry (LC−TOF-MS) were obtained for structural identification studies. The analyses
of the metabolite of chloropicrin were performed by headspace−gas chromatography
(HS−GC)−MS using selected ion monitoring (SIM). Sulfur mustard and capsaicinoids were
metabolized in vitro mainly by oxidation reactions and glutathione (GSH) conjugations.
Several novel metabolites were identified however their clinical usefulness to serve as
biomarkers of exposure in humans requires further studies. In addition, chloropicrin was
found to metabolize into nitromethane in vitro, especially in the presence of GSH.
Quantitative LC−MS/MS methods were used in the successful detection of saxitoxin and
two b-lyase metabolites of sulfur mustard and the HS−GC−MS method was used for the
analyses of nitromethane; all of which were optimized and fully validated for verification
purposes. All fit for purpose methods were found to be accurate and linear and fulfilled
general identification criteria.
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9GENERAL ABBREVIATIONS
ANOVA analysis of variance
AOAC Association of Official Analytical Chemists
APCI atmospheric pressure chemical ionization
API atmospheric pressure ionization
APPI atmospheric pressure photoionization
BWA biological warfare agent
CI chemical ionization
CV coefficient of variation
CWA chemical warfare agent
CWC Chemical Weapons Convention
CYP cytochrome P450
Da Dalton (atomic mass unit)
DNA deoxyribonucleic acid
EI electron ionization
EIC extracted ion chromatogram
ELISA enzyme-linked immunosorbent assay
ER endoplastic reticulum
ESI electrospray ionization
EU European Union
FDA Food and Drug Administration
FLD fluorescence detector
GC gas chromatography
GC−MS/MS gas chromatography−tandem mass spectrometry
HILIC hydrophilic interaction chromatography
HPLC high-performance liquid chromatography
HRMS high-resolution mass spectrometry
HS−GC headspace−gas chromatography
ICH International Conference on Harmonisation
i.d. internal diameter
i.p. intraperitoneal injection
ISTD internal standard
LC liquid chromatography
LC−MS/MS liquid chromatography−tandem mass spectrometry
LD50 lethal dose (sufficient to kill 50% of a population of test animals)
LLE liquid-liquid extraction
LLOQ lower limit of quantitation
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LOD limit of detection
LOQ limit of quantitation
MBA mouse bioassay
[M-H]- deprotonated molecule
[M+H]+ protonated molecule
MS mass spectrometry
MS/MS tandem mass spectrometry
MSn multiple-stage scanning
m/z mass-to-charge ratio
NMR nuclear magnetic resonance spectroscopy
OC oleoresin capsicum
OPCW the Organisation for the Prohibition of Chemical Weapons
PSP paralytic shellfish poisoning
PTFE polytetrafluoroethylene
PVDF polyvinylidene fluoride
QqQ triple quadrupole
Q-TOF quadrupole time-of-flight
ROP recommended operating procedure
ROS reactive oxygen species
RPLC reversed phase liquid chromatography
rpm rounds per minute
RSD relative standard deviation
Rt retention time
SIM selected ion monitoring
S/N signal-to-noise ratio
SPE solid phase extraction
SPME solid phase micro extraction
SRM selected reaction monitoring
TIC total ion chromatogram
TRPV1 vanilloid subtype 1 receptor
UHPLC ultra-high performance liquid chromatography
WADA World Anti-Doping Agency
WW World War
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ABBREVIATIONS OF CHEMICALS
ACN acetonitrile
CAP capsaicin, 8-methyl-N-vanillyl-6-nonenamide
DCM dichloromethane
DHC dihydrocapsaicin, N-(4-hydroxy-3-methoxybenzyl)-8-methylnonanamide
DMSO dimethyl sulfoxide
DNA deoxyribonucleic acid
DTT dithioreitol
FA formic acid
GSH glutathione
GTX 1 gonyautoxin 1
HDO bis(2-chloroethyl)sulfoxide
HETE hydroxyethylthioethyl
MeOH methanol
MgCl2 magnesium chloride
MSMTESE 1-methylsulfinyl-2-[2-(methylthio)ethylsulfonyl]ethane
NADPH nicotinamide adenine dinucleotide phosphate
SBMSE 1,1’-sulfonylbis[2-(methylsulfinyl)ethane]
SBMTE 1,1’-sulfonylbis[2-(methylthio)ethane]
SBSNAE bis(N-acetylcysteine)conjugate, 1,1’-sulfonylbis[2-S-(N-
acetylcysteinyl)ethane]
STX saxitoxin
TDG thiodiglycol, 2-(2-hydroxyethylsulfanyl)ethanol
TDGO thiodiglycol sulfoxide, 2-(2-hydroxyethylsulfinyl)ethanol
TiCl3 titanium trichloride
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1. INTRODUCTION
Toxic chemicals have been used as weapons and for homicide since ancient times. The use
of such chemicals was quite small-scale initially, and their impact was rather limited due to
the lack of knowledge about chemistry and toxicology. At the beginning of the 19th century,
however, the understanding and knowledge of the science of chemistry grew rapidly and this
was accompanied by the growth and development of the chemical industry. Increasing
knowledge on the toxicological effects of chemicals and the innovation of large-scale
production provided the basis for their first use as weapons of mass destruction in the First
World War (WW I). That event started an era of continuous effort to develop evermore
effective chemicals or toxins to be used in warfare [1,2].
Chemical or biological warfare agents (CWA, BWA) are chemicals, toxins or micro-
organisms whose synthesis or culturing on a mass scale are intended for use in military
conflicts in order to kill, seriously injure or incapacitate exposed persons. The types and
numbers of CWAs and BWAs are manifold and they exert countless different toxicological
effects. CWAs and BWAs are usually divided into groups based on their effects on victims,
e.g. choking agents, vesicants, nerve agents, blood agents, irritants, incapacitants and various
biological agents [3,4].
There were several other occasions after WW I and especially after WW II when CWAs
were used for military or terrorist purposes. Countermeasures against the use of CWAs have
been taken since the beginning of the 19th century. The Organisation for the Prohibition of
Chemical Weapons (OPCW) was established to implement the Chemical Weapons
Convention (CWC), which entered into force in 1997. The CWC prohibits the development,
production, stockpiling and the use of chemical weapons. Its goal is to destroy the existing
stockpiles and prevent new production coming on stream [5].
The fate of some CWA stockpiles is however uncertain. Many CWAs were simply
abandoned, buried or dumped into the seas. In addition, toxic chemicals are still used as legal
riot  control  agents,  in  the  chemical  industry  for  various  processes  and products  or  even as
pesticides in agriculture. Humans and animals could thus be accidentally exposed to these
chemicals in incidents that occur in everyday occupational activities. It is important that
existing and novel methods used in modern analytical chemistry be further developed to
detect possible exposures to these chemicals and to gain more knowledge about their
metabolism and toxicological effects. Validated analysis methods and unequivocal
metabolites, such as biomarkers of exposure, are needed for verification analysis [6-8].
The conventional methods for CWA analyses of environmental samples have been
gathered into Blue Books as recommended operating procedures (ROPs) [9,10], which have
been tested under international collaboration. The main analytical method for verification
analysis of intact CWAs and their degradation products is gas chromatography (GC)
combined with different types of detectors, due to their volatility and relatively low
molecular weights [11]. However, the most reliable retrospective detection and confirmation
of exposure of these chemicals are achieved by analyzing biomarkers from biological
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samples, mainly from studied animals or exposed persons. Metabolites in biological samples
of CWAs are analyzed by hyphenated methods of liquid chromatography–tandem mass
spectrometry (LC−MS/MS) or gas chromatography–tandem mass spectrometry
(GC−MS/MS) [12-14].
The research presented in this thesis focuses on four different toxic and incapacitating
chemicals; sulfur mustard, capsaicinoids, chloropicrin and saxitoxin; all of which have
different chemical properties and toxicological mechanisms [8,15]. These chemicals are also
listed in the CWC or used for riot control. In vitro methods are applied to study metabolism
and various mass spectrometric methods are used to screen and identify the formed
metabolites. The validation of analyses methods are performed for four known metabolites
and results are evaluated in the studies summarized in this thesis.
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2. REVIEW OF THE LITERATURE
2.1 Metabolism of toxic and incapacitating chemicals
Toxic and incapacitating chemicals are considered to be exogenous compounds, also known
as xenobiotics, since they do not originate in human bodies. Upon exposure to such
chemicals, most xenobiotics are eliminated as metabolites, which are the products of
enzymatic biotransformation reactions. The effects of these reactions are to transform the
original xenobiotic into more hydrophilic and inactive forms, which enables these
metabolites to be easily excreted from the body. These metabolic reactions are usually
divided into phase I and phase II reactions. Phase I reactions are fuctionalizing reactions, i.e.
oxidation, reduction and hydrolysis, and they are mostly catalyzed by cytochrome P450
(CYP) enzymes. These reactions typically prepare the molecule for phase II reactions, which
are conjugation reactions, such as methylation, acetylation, sulfatation, glucuronidation, or
conjugation with glutathione (GSH) or amino acids [16].
The toxicity of the xenobiotics could result directly from their chemical or biological
properties in the original molecular form or from their reactive intermediates that are formed
during the metabolism, which is a process that is also known as bioactivation [17]. The
metabolism studies conducted on xenobiotics are mostly related to the development of novel
medicinal drugs, since drugs are the widest group of xenobiotics to which humans are
exposed. Metabolism of many xenobiotics, including medicinal drugs and toxic compounds,
occur  mainly  in  the  liver.  The  general  approach  is  to  use in vitro metabolism studies to
predict in vivo metabolite profiles and pharmacokinetic parameters in the absence of direct
knowledge about in vivo metabolism in humans or animals, before actual in vivo studies are
conducted [18]. The in vitro approach alone cannot simulate the complexity of metabolic and
physiological interactions of the whole human body and replace the in vivo studies entirely,
which is why in vitro systems are always considered as models for comprehensive studies to
characterize a xenobiotic [19,20].
In vitro metabolism studies are usually performed by using various sources of enzymes,
including the recombinant enzymes and liver subcellular fractions such as microsomes,
cytosol, and the S9 fraction. Other sources of enzymes originate from the whole-cell systems
such as hepatocytes or other cell lines [21]. Recombinant enzymes and liver subcellular
fractions provide the most convenient way to study phase I and II metabolism where the
whole-cell systems give a more complete picture of metabolism and reliable in vivo/in vitro
correlation [19,22].The toxicity and metabolic profiles of xenobiotics are always investigated
using in vivo animal models [21] or clinical studies on humans conducted in new drug
development to confirm and complement the initial findings of in vitro metabolism studies
[23]. The use of animals in studies on toxicology and chemical exposure raises questions of
ethics; particularly regarding chemicals that are known to be toxic or incapacitating. Methods
that alleviate or minimize potential pain, suffering, or distress, and enhance welfare for the
animals are preferable [24]. Only limited amounts of toxicity data and information of
metabolism in humans have been provided for the CWA related toxic and incapacitating
15
chemicals, and most of it is based on the analysis of accidentally or deliberately exposed
persons [12]. The understanding of metabolism of the toxic and incapacitating chemicals is
necessary for the verification of exposure and also for the appropriate treatment of exposed
persons and might lead to the development of an antidote [25].
2.2 Mass spectrometry and chromatography in metabolism studies
The study of the metabolic fate of xenobiotics requires the identification, structural
characterization and quantification of the metabolites [26,27]. These analyses are performed
on samples obtained from complex biological matter, such as in vitro matrices, urine,
plasma, bile or feces, where the concentrations of the metabolites may be extremely low.
Therefore, highly specific and sensitive analytical methods are needed to detect such trace
amounts.
MS is the only currently available analytical method for trace level metabolite screening
and identification that combines enough sensitivity, structural information and general
applicability and is usually hyphenated with chromatographic methods such as GC or
LC [28]. The GC−MS methods provide trace level quantification of the metabolites in
complex mixtures but they often require laborious sample preparation to increase the
volatility of the analytes prior to analysis [29]. In addition, chemical decomposition or
thermal lability of conjugated metabolites provides limited utility for metabolism studies by
GC−MS alone.
LC−MS/MS enables the identification and quantification of polar and non-volatile
metabolites with a broad range of molecular masses without derivatization of the analytes.
Several combinations, including various ionization methods and mass analyzers provide
excellent sensitivity, specificity and quantitative analyses of the metabolite concentrations at
trace levels [30]. However, the lack of reference chemicals or labeled internal standards
(ISTDs) is the limiting factor of MS in metabolite quantification.
2.2.1 Sample preparation for metabolite identification
Sample preparation is usually needed prior to GC−MS or LC−MS analysis to derivatize or
concentrate the target analytes, and to remove or minimize interfering factors of biological
matrices. The efficiency of sample preparation directly affects the limit of detection (LOD)
and accuracy of the MS analysis. The main interfering substances in the matrices of
biological samples are usually proteins, peptides, lipids and inorganic salts. The sample
preparation method for metabolite screening and identification should be reproducible and
have high recovery due to the low concentrations and variable polarities of the unknown
metabolites [31].
A protein precipitation method is used for biological samples, such as in vitro matrices
and  plasma,  to  generally  remove  endogenous  matrix  components.  The  addition  of  two  to
three volumes of organic solvent, such as acetonitrile (ACN) or methanol (MeOH) will
precipitate significant parts of the proteins and salts [32]. Their addition will also dilute the
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sample and then minimize the possible ion suppression in the MS analysis caused by
remaining endogenous compounds.
Solid phase extraction (SPE) is more effective and selective purification technique than
protein precipitation and it is typically used for liquid samples such as urine, bile and plasma.
The metabolite concentrations are usually lower in these samples than in vitro incubations.
SPE concentrates the samples but it also tends to require reference standards for the method
development and possibly labeled ISTDs to determine the recovery. SPE is therefore mainly
used for known target metabolites [33,34].
Other sample preparation methods exist including: liquid-liquid extraction (LLE),
solvent exchange and derivatization are usually performed, especially in samples to be
subjected to GC−MS analyses, in order to increase the volatility and decrease the polarity of
the analytes. However, if the metabolites are volatile enough, headspace (HS) methods
enable direct GC−MS analyses even from aqueous samples after short heating times [35,36].
2.2.2 Ionization methods, mass analyzers and data acquisition
MS is an analytical method whereby ions are separated by their mass-to-charge ratio (m/z)
and thus prior to the analysis, the sample components must be be ionized. Atmospheric
pressure ionization (API) methods are the most suitable for LC−MS based analysis.
Electrospray ionization (ESI) in addition to the atmospheric pressure chemical ionization
(APCI) are the mostly widely used API methods [26,28]. Atmospheric pressure
photoionization (APPI) has provided promising results [37] however it is still less used in
routine applications.
The  ESI  method  provides  a  softer  ionization  of  the  analytes  than  APCI,  since  only  a
small amount of fragmentation is produced. Conventionally, APCI allows higher flow rates
than ESI however, in modern instruments this feature is no longer an issue. Typically, APCI
is unsuitable for thermally labile molecules and is also generally limited to low molecular
mass analytes (< 2000 Dalton (Da)) [38]. APCI is well suited for neutral molecules and does
not suffer from the matrix effects as much as ESI. Both APCI and ESI produce either
positive or negative protonated molecules ([M+H]+ or ([M-H]-) however, adducts and
multiple charged ions can also be formed, especially in ESI [39]. In addition, ESI is
susceptible to matrix effects, which are a major concern in bioanalysis [40]. Both positive
and negative ionization modes are important to utilize in metabolism studies, however a
major part of the metabolites are ionized better in the positive ion mode. Nevertheless, the
negative ion mode can be used in the detection of GSH, sulfate and glucuronide conjugates
[41-43].
Various mass analyzers and data acquisition methods have been used for the qualitative
and quantitative analyses of metabolites. Triple quadrupole (QqQ) and ion trap analyzers
have been used for their various MS/MS and multiple-stage scanning (MSn) capabilities [44],
whereas high-resolution (HR)MS analyzers, such as quadrupole time-of-flight (Q-TOF) or
Orbitrap, are widely used due to their improved resolution and ability to measure masses
accurately [45,46].
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Qualitative metabolite analysis can be divided into two parts; screening and structure
identification. Screening methods include full scan MS, neutral loss scan, precursor ion scan
and selected ion monitoring (SIM) or selected reaction monitoring (SRM). Full scan MS is
non-selective and provide m/z measurements for all ionisable analytes by all current mass
analyzers. Its drawback is the presence of interfering ions from complex matrices, which
leads to confounding and intereference problems in the detection of the metabolite ions at
low concentrations. This problem can be minimized by using the appropriate gradient elution
in high-performance liquid chromatography (HPLC) or ultra-high performance liquid
chromatography (UHPLC) prior  to  full  scan  analyses  or  by  using  an  HRMS analyzer  with
high selectivity. The background subtraction of the blank sample from the in vitro sample to
reduce the background is also possible, if the matrices of these two samples are similar [47].
Neutral loss and precursor ion scan modes enable group-specific detection of metabolites
and require only minimal knowledge of the metabolite structures. These data acquisition
methods are provided by tandem mass analyzers, such as QqQ, hybrid quadrupole time-of-
flight and triple quadrupole−linear ion trap MS. Neutral loss acquisition is usually applied
for detection of phase II metabolites, such as GSH, sulfate or glucuronide conjugates using
neutral losses of 129, 80 or 176 Da, respectively [29,48]. Alternatively, the precursor ion
scan mode is useful for the screening of metabolites that produce the same specific product
ion in their spectra. Both approaches are specific tools for metabolite detection however, and
some endogenous compounds could result in false positives, especially when using the
neutral loss acquisition mode. The selectivity could be increased by using HRMS [48].
The SRM mode is generally used in quantitative target analysis since it offers high
selectivity, specificity, and sensitivity but also requires the information for analyte
fragmentation. However, recently it has been adapted for use in metabolite screening,
because after the determination of the SRM reactions of the parent chemical, SRM ion pairs
of the most common phase I and II metabolites could be predicted or generated from
information obtained by another data acquisition method [49,50]. The advantage of the SRM
screening approach is that its high sensitivity enables detection of trace levels of metabolites
in complex biological matrices.
There are several data acquisition methods available for the structural identification of
metabolites such as accurate mass measurement, product ion scan (MS/MS) and MSn
scan [51]. Accurate mass measurements, provided by HRMS instruments, are used to
determine the elemental compositions of the metabolites and can offer an unequivocal
structure confirmation. MS/MS and MSn scannings can be performed with and without data
dependent acquisition by ion trap instruments. The conventional MS/MS mode is also
applicable for all the tandem mass analyzers. Identification of metabolite structures is
typically achieved by interpreting the fragments of the metabolite in the MS/MS spectrum
and, whenever possible from the original chemical. MSn scanning enables the generation of
fragmentation tree (MS → MS2 → MS3 → MS4), which is a useful feature when determining
the site of metabolic alteration in the molecule.
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2.2.3 Validation of analytical methods and identification criteria
All guidelines for analytical method validation are devoted to the same outcome, which is the
final results generated during the sample analysis of a given matrix must be accurate and
precise within acceptable uncertainty requirements. However, the variability between the
details of definitions and terminology is broad. The most known analytical validation
documentations have been published by the following bodies: Eurachem, the Association of
Official Analytical Chemist International (AOAC International), the International
Conference on Harmonisation (ICH) and the US Food and Drug Administration (FDA) [52-
55].
The validation process as an analytical method must be fit for purpose. In brief, fitness
for purpose means that the associated uncertainty of a given method is adequate given the
needs of the application area. The FDA guidance for the quantitative bioanalytical method
validation should be a proper choice [55]. The main validation parameters defined in the
FDA guidance are listed in Table 1. The basic components investigated during the validation
are accuracy, precision, selectivity, sensitivity, range of linearity and reproducibility. In
addition, analyte recovery, carryover, matrix effects and sample stability are preferable to be
determined for full bioanalytical method validation. Full validation is used when the
validation process is performed for the first time. Partial validation or cross-validation for
existing methods is possible when either modification for the already validated method is
performed or when there is a need for comparison of validation parameters within two or
more bioanalytical methods, respectively. The guidance provides general recommendations
for the validation, which can be adjusted or modified depending on the type of analytical
method used.
Table 1 Summary of the FDA guidance for bioanalytical method validation [55].
Parameter FDA guidance
Accuracy Should be measured using a minimum of five determinations per
concentration. The deviation of the mean value should be ±15% of
the actual except at the lower limit of quantitation (LLOQ), where it
shoud be no more than ±20%.
Precision Should be measured using a minimum of five determinations per
concentration. The precision should be ±15% of the coeffiecient of
the variation (CV) except at the LLOQ, where it shoud be no more
than ±20%. Is usually subdivided into within-batch and between-
batches.
Selectivity Analysis of blank samples of the biological matrix should be
obtained from at least six sources and tested for interference
especially at the LLOQ.
Range of reliable response
(calibration curve)
The calibration curve should be prepared in the same biological
matrix as the samples and should consist of blanks (with and without
an ISTD and 6-8 non-zero samples.
Recovery Recovery also known as extraction efficiency need not be 100% but
should be consistent, precise and reproducible. Should be performed
at three concentrations (low, medium, high) using biological matrix.
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Identification criteria for analytical methods have been established in addition to
quantitative method validation. These criteria play important roles, especially in cases for
which trace level results of bioanalyses must be reliable enough to stand up to legal
examination in court, such as in doping control, forensic toxicology or the verification of
CWAs. In most cases, the analyst does not know the exact chemicals to look for but has to
produce unequivocal evidence of the presence of well-defined or forbidden substances in
biological matrices. The identification criteria have been defined for the advanced analytical
approaches, particularly for MS based techniques by several international authorities
including the European Union (EU) Comission [56] and the World Anti-Doping Agency
(WADA) [57].
Since the year 2010, the OPCW has organized the confidence building exercises for
biomedical sample analysis with their own specified instructions for identification [58]. The
general criteria by the EU, WADA and OPCW for chromatographic separation by GC or LC
and for MS identification are listed and compared in Tables 2 and 3.
Table 2 Comparison of identification criteria for GC, LC and and MS [55,56,58].
Chromatographic
separation (GC, LC) EU WADA OPCW
Retention time (Rt) GC ±0.5%LC ±2.5%
GC ±1% or ±0.2 min
LC ±2% or ±0.4 min
GC ±0.1 min
LC ±0.2 min
S/N ≥3:1 >3:1 ≥1:5
MS identification
Full scan MS and MS/MS
All diagnostic ions,
when their relative
intensity is >10% a
All diagnostic ions,
when their relative
intensity is >10% a
All diagnostic ions,
when their relative
intensity is >10% a
SIM Preferably at least themolecular ion b ≥ 3 diagnostic ions ≥2 diagnostic ions
SRM nd. 2 transitions c ≥1 transition
HRMS
Resolution >10000 for
the entire mass range
at 10% valley
nd.
Resolution >10000
for the entire mass
range at 10% valley
a In the reference spectrum of the calibration standard
b The other selected diagnostic ions should not originate from the same part of the molecule
c When more than one transition is monitored, the relative abundance of a diagnostic ion shall be determanated
nd. = not defined
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Table 3 Maximum tolerances for q/Q ratios for identification by the EU [56] and WADA [57].
EU Relative abundance
(% of the base peak)
EI−GC−MS
(relative)
CI−GC−MS, GC−MSn
LC−MS, LC−MSn (relative)
>50% ±10% ±20%
>20-50% ±15% ±25%
>10-20% ±20% ±30%
≤10% ±50% ±50%
WADA Relative abundance
(% of the base peak)
EI−GC−MS, CI−GC−MS, GC−MSn
LC−MS, LC−MSn
>50% ±10% (absolute)
>25-50% ±20% (relative)
>5-25% ±5% (absolute)
<5% ±50% (relative)
q/Q = quolifier/Quantifier ion or transiotion relation
2.3 Metabolism of selected chemicals and their analysis
2.3.1 Sulfur mustard
Sulfur mustard, bis-(2-chloroethyl)sulfide, is a vesicant type chemical warfare agent and a
Schedule I chemical as defined by the CWC [5]. It was first used during the WW I and more
recently in Middle East conflicts [3]. Sulfur mustard is an oily yellowish liquid at room
temperature, which can easily penetrate clothing and skin.
The clinical picture of sulfur mustard poisoning is quite well known because of the
thousands of victims during the WW I and the Iran-Iraq conflict. It causes cutaneous blisters,
respiratory tract damage, eye lesions and depression of bone marrow activity [59]. Sulfur
mustard is also classified by the International Agency for Research on Cancer as being
carcinogenic to humans [60]. There is no specific antidote available, but much effort has
been made by to find an antidote using in vivo studies with mice, rats and swine [61-63].
The toxicology and metabolism of sulfur mustard are complex and not fully understood.
It has two relatively non-selective electrophilic positions and it forms an episulfonium ion by
intramolecular nucleophilic substitution (Figure 1). This highly reactive intermediate can
form covalent bonds with available nucleophiles.
Figure 1 Formation of episulfonium ion from sulfur mustard [95].
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The high toxicity, metabolism and distribution of sulfur mustard have also been studied
in vivo in mice [64], rats [65-70], monkeys [71], guinea pigs [72,73] and rabbits [74]. In
contrast, in vitro studies have used human blood [72,75-83] or various cultured cells [84-87].
Many of these metabolites have been identified in human casualties after accidentally or
deliberate exposure to sulfur mustard [88-95]. Chemical analysis of post-mortem tissues
from  an  exposed  person  has  shown  the  main  accumulation  is  in  the  adipose  tissue,
particularly in the subcutaneous fat, brain, kidney, liver and lungs [96]. A somewhat similar
distribution has been reported for rodents after percutaneous or inhalation exposures [97].
The known biochemical reactions of sulfur mustard include hydrolysis, oxidation of
sulfur, conjugation with GSH and alkylation of deoxyribonucleic acid (DNA), proteins and
cell membranes. Several in vivo metabolites have been detected in humans and in animal
models that could be used as biomarkers of sulfur mustard exposure. These metabolites,
sample matrices and analyses techniques are listed in Tables 4 and 5.
The major urinary excreted metabolites of sulfur mustard in humans and animals are the
hydrolysis products: thiodiglycol (TDG) and thiodiglygol sulfoxide (TDGO), and GSH
derived b-lyase metabolites 1,1-sulfonylbis-[2-(methylsulfinyl)ethane] (SBMSE) and 1-
methylsulfinyl-2-[2-(methylthio)ethylsulfonyl]ethane (MSMTESE) and bis(N-
acetylcysteine) conjugate (1,1’-sulfonylbis[2-S-(N-acetylcysteinyl)ethane, SBSNAE) whose
respective structures and analysis techniques are listed in Table 4. The validity of TDG and
TDGO as biomarkers of exposure is equivocal, since both occur at trace levels (0.2-
20 ng/ml) in human urine from unclear origin [98,99]. However, after exposure to sulfur
mustard the sum concentration of both markers in urine is abnormally high (2.2-104 ng/ml
within two weeks after exposure) [88,93,95,99]. In contrast, no background levels or
interference factors have been detected for b-lyase metabolites [100,101] or SBSNAE [92].
The measured concentrations of SBMSE and MSMTESE have been 12.7-183 ng/ml and 2.2-
138 ng/ml, respectively, within four days after exposure [95]. However, SBSNAE appears to
be a minor metabolite in humans as indicated by results of the analysis of samples from
victims after accidental exposures (~1-3.1 ng/ml) [92,93]. Recently, S-oxidized sulfur
mustard, bis(2-chloroethyl)sulfoxide (HDO) was proposed as biomarker, since it was
detected in human plasma and blister exudate samples of sulfur mustard exposed persons
[95]. In addition, sulfur mustard alkylates DNA and blood proteins (e.g. haemoglobin and
albumin) by forming covalent bonds to their critical nucleophilic sites. Adducts found in in
vivo samples could be used as unequivocal biomarkers of exposure (Table 5). N7-HETE-
Guanine and N-HETE-Valine have been the most abundant and detected biomarkers from
blood samples [70,89,90,95].
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Table 4 Major in vivo metabolites of sulfur mustard derived from hydrolysis, oxidation, GSH conjugation and b-lyase metabolism.
Metabolite Type of
metabolism
Structure Sample matrix Analysis method Reference
HDO Oxidation product
Plasma and blister exudate (human)
Plasma (rat) UPLC-MS/MS (SRM)
[95]
[69,70]
MSMTESE GSH conjugation+b-lyase metabolism
Urine (human)
Plasma and blister exudate (human)
Urine (rat)
Plasma (rat)
GLC−MS (SIM)
EI−GC−MS/MS
HPLC−MS/MS (SRM)
EI−GC−MS/MS
HPLC−MS (CID)
UPLC−MS/MS (SRM)
[88]
[93,95]
[91]
[95]
[65]
[69]
SBMSE GSH conjugation+
b-lyase metabolism
Urine (human)
Plasma and blister exudate (human)
Urine (rat)
Plasma (rat)
GLC−MS (SIM)
EI −GC−MS/MS
HPLC−MS/MS (SRM)
EI−GC−MS/MS
HPLC−MS (CID)
UPLC−MS/MS (SRM)
[88]
[93,95]
[91]
[95]
[65]
[69]
SBSNAE
GSH conjugation+
mercapturic acid
breakdown
Urine (human)
Plasma (rat)
HPLC−MS/MS (SRM)
UPLC−MS/MS (SRM)
[92,93]
[69]
TDG Hydrolysis
Urine (human)
Urine (rat)
Urine (rabbit)
NCI−GC−MS (SIM)
HPLC−MS (CID)
NCI−GC−MS
[88,93,95,99]
[65]
[74]
TDGO Hydrolysis andoxidation
Urine (human)
Urine (rat)
Urine (rabbit)
NCI−GC−MS (SIM)
HPLC−MS (CID)
NCI−GC−MS
[88,93,95,99]
[65]
[74]
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Table 5 Major in vivo metabolites of sulfur mustard derived from alkylation of DNA and proteins.
Metabolite Type of
metabolism
Structure Sample matrix Analysis method Reference
Bis-G a
DNA adducts
Blood (human)
Derma (rat)
Urine (rabbit)
UPLC−ESI−MS/MS (SRM)
[95]
[70]
[107]
N3-HETE-Adenine
Blood (human)
Derma (rat)
Urine (rabbit)
UPLC−ESI−MS/MS (SRM)
[95]
[70]
[107]
N7-HETE-Guanine Blood (human)
Derma (rat)
Urine (rabbit)
Urine (guinea pig)
Immunoplot assay
UPLC−ESI−MS/MS (SRM)
HPLC−ESI−MS/MS (SRM)
[90]
[95]
[70]
[107]
[72]
O6-HETE-Guanine
Blood (human)
Derma (rat)
Urine (rabbit)
UPLC−ESI−MS/MS (SRM)
[95]
[70]
[107]
N-HETE-Valine Haemoglobin
adduct
Blood (human)
Blood (guinea pig)
Blood (rat)
NCI−GC−MS
[89,90,95]
[72]
[68]
N-HETE-Histidine - Blood (human) HPLC−ESI−MS/MS (SRM) [89]
S-HETE-Cys-Pro-Phe b
Albumin adduct
Blood (human) µLC−ESI−MS/MS (SRM)HPLC−ESI−MS/MS (SRM)
[78]
[94]
S-HETE-Cys-Pro-Tyr Blood (rat) HPLC−ESI−MS/MS (SRM) [68]
a bis[2-(guanin-7-yl)ethyl]sulfide, b Cysteine-Proline-Phenyl alanine/Tyrosine
HETE = hydroxyethylthioethyl
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The mostly used analysis methods for detecting sulfur mustard biomarkers are
GC−MS/MS and LC−MS/MS, however a few immunodiagnostic methods are also available
[81,102,103]. Hydrolysis products (TDG and TDGO) are derivatized prior to GC−MS
analysis [88,93,95,98,99]. Usually, TDGO has been reduced back to TDG using titanium
trichloride (TiCl3) and they are analyzed together. In addition, SBMSE and MSMTESE are
reduced to 1,1’-sulfonylbis[2-(methylthio)ethane] (SBMTE) before GC−MS/MS analysis
[88,93,95,101,104]. However, the TiCl3 reduction may cause interfering background to the
biological samples. SBMSE and MSMTESE, as well as SBSNAE and HDO have been also
analyzed by LC−MS/MS after protein precipitation or SPE purification, which have been
proved to be practical [91,92,95,105]. DNA and protein adducts need enzymatic or acidic
digestion prior to analysis by the LC−MS/MS [78,90,94,95,106,107]. Among these adducts,
only N-HETE-Valine has been analyzed by GC−MS after selective derivatization with a
modified Edman reagent [89,90,95].
2.3.2 Capsaicinoids
Capsaicinoids are the active chemicals of oleoresin capsicum (OC), which is an oily extract
of chilli peppers (Capsicum sp.) used in pepper spray products (i.e. OC spray or pepper
gas) [4]. Pepper sprays are one of the most frequently used weapons of self-protection of law
enforcement personnel and civilians. However, the use of pepper sprays, due to their
possibly dangerous health effects has been under much debate and the regulation of use and
control of pepper spray products vary greatly between countries [108]. Apart from the pepper
spray products, humans can also be exposed to capsaicinoids by consuming spicy foods or in
clinical applications such as topical analgesics or weight loss supplements [109-111].
Capsaicinoids are a group of vanillyl fatty acid amides. OC extract is a highly variable
and complex mixture whose composition depends on varying extraction conditions and
maturity of the chili peppers. The major part of the extract comprises capsaicin, 8-methyl-N-
vanillyl-6-nonenamide (CAP) and dihydrocapsaicin, N-(4-hydroxy-3-methoxybenzyl)-8-
methylnonanamide (DHC) at relative proportions of 45-55% and 40-50%, respectively [112].
Figure 2 shows the chemical structures of CAP and DHC. The amount of CAP varies in the
pepper spray products between 1% and 15% according to manufacturers [108].
Figure 2 Chemical structures of capsaicin and dihydrocapsaicin.
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CAP is a highly selective agonist for vanilloid subtype I receptors (TRPV1), which are
expressed mainly in the primary sensory neurons and are known to mediate the sensation of
burning and localized inflammation [113,114]. Exposure to pepper sprays produces burning
pain in the skin and mucosal membranes, coughing, and temporary loss of vision, which
result in the total incapacity of the targeted person to act for variable time periods [115]. Low
concentrations of capsaicinoids induce irritation and coughing, whereas high doses can lead
to bronchoconstriction and dyspnea [116,117]. Inhalation studies with animals have shown
marked acute inflammation, epithelial cell dysplasia and necrosis in the upper and lower
respiratory tract. The doses causing the lesions were estimated to be about the same as
human could receive during 5-10 s exposure to pepper spray [118]. Exposures to
capsaicinoids through diet or in clinical applications have not been reported to cause notable
health risks, whereas an exposure of capsaicinoids-containing spray to the eye area can be
harmful [119-122]. CAP has also been suggested to increase the lethality of cocaine [123].
Extensive studies have been conducted on CAP from the clinical applications
perspective due to its widespread consumption [124-127]. However, the uptake and
metabolism of capsaicinoids via the pepper spray inhalation route in humans, or the
biomarkers of pepper spray exposure have hitherto not been elucidated. Lipophilic
capsaicinoids are readily absorbed from the mucosal membranes and they were also shown
to be metabolized extensively in the liver and less efficiently in the respiratory system [128].
Capsaicinoids undergo phase I and phase II metabolic reactions, which involve oxidative and
non-oxidative pathways, in addition to GSH conjugations [124,126,128-134]. The formation
of capsaicin glucuronide conjugate in vivo in rats has been reported [135].
Previously, Reilly et al. characterized in vitro metabolites M1-M9 for CAP (Figure 3),
whose formation was mediated by CYP enzymes in pooled human liver microsomes and
detected by LC−MS/MS and LC–nuclear magnetic resonance spectroscopy (LC−NMR)
[128,136]. The main targets for metabolic reactions have shown to be in aliphatic chain,
amide bond and aromatic ring. M1 is formed by the covalent bonding of the w-1-carbon to
the amide bond, which forms a macrocycle structure. M2 and M3 are w- and w-1-substituted
alcohols, whereas M4 is characterized as alkyl terminal diene. M5 and M7 are two aromatic
hydroxylation products. M6 is identified as O-demethylated catechol, M8 as an oxygenated
imide and M9 as an imide. The GSH conjugation of capsaicin was found to target within the
aromatic ring or the carbon between the aromatic ring and the amide bond [129].
In spite of the extensive in vitro metabolism studies on CAP, its identified metabolites
mentioned above have not been detected in vivo in humans. Unmetabolized capsaicinoids
were detected in rats’ blood and tissue samples by LC−MS/MS after nose-only inhalation
[137]. Similarly, unaltered CAP and DHC were measured from equine plasma samples by
UHPLC−MS/MS for doping control of race-horses [138]. Both methods used LLE and
ISTDs for sample preparation and quantification, respectively.
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Figure 3 Previously identified CYP-related metabolites (M1-M9) of capsaicin [128].
2.3.3 Chloropicrin
Chloropicrin (trichloronitromethane, CCl3NO2) is a small, volatile compound, which is listed
as a Schedule 3 chemical in the CWC [5]. Chloropicrin is a strong lung irritant and
lacrimator; therefore it was used as a chemical warfare agent during World War I [139].
Nowadays, it is widely used as a soil fumigant against insects, fungi and nematodes [140]. At
high temperatures it decomposes forming toxic gases such as nitrogen oxides, nitrosyl
chloride and phosgene. Small amounts of chloropicrin are also formed in drinking water after
chlorination, as a disinfection byproduct, and it is potentially cytotoxic and genotoxic agent
[141,142]. The high voltatility of chloropicrin causes its main target tissues of exposure to be
the  eyes,  the  respiratory  tract  and  the  skin.  Airborne  concentrations  of  0.15  ppm  could  be
enough to cause irreversible and serious health effects [143]. Lacrimation, irritating cough
and chest pain have been reported after accidental exposure to chloropicrin [144]. Other
observed symptoms included breathing difficulties, nausea and vomiting [145].
Toxicology and metabolism of chloropicrin are not well known. In vitro testing
implicates genetic toxicity in the presence of an exogenous metabolic system or GSH
[141,142,146,147]. Pesonen et al. have recently studied in vitro toxicity of chloropicrin by
using human retinal pigment epithelial and lung epithelial cells [148,149]. Chloropicrin was
shown to increase the expression levels of the endoplastic reticulum (ER) stress-related
proteins in addition to the release of large amounts of reactive oxygen species (ROS) in an
epithelial cell line that originated from human retina [148]. In addition, microscopy of the
lung epithelial cells revealed massive vacuolization and the number of apoptotic cells
increased with the chloropicrin concentration as assessed by flow cytometry [149].
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The only in vivo studies that have been carried out in mice, found a few metabolic
products in the urine, including: nitromethane and raphanusamic acid [150,151]. The CYP
enzymes, glutathione S-transferase and b-lyase reactions were initially thought to be the
contributing pathways, however the enzymes responsible for the metabolism are still
unknown. The structures of chloropicrin and nitromethane are presented in Figure 4.
Figure 4 Chemical structures of chloropicrin and nitromethane.
In previous studies, chloropicrin and its degradation products have been analyzed in
water samples by HS−GC−MS [152] and by solid phase microextraction (SPME)−GC−MS
[153]. Alwis et al. detected nitromethane in human blood by SPME−GC−HRMS after in
vitro addition of chloropicrin [36]. Those authors also reported that the non-exposed blood
samples gave baseline concentrations of nitromethane (0.28-3.79 ng/ml). It is reasonable to
assume that concentrations of nitromethane in blood after chloropicrin exposure in humans
would be a somewhat higher than this baseline. The SPME−GC−HRMS method provides
sensitive and accurate measurement for nitromethane, however the used volume of blood
samples (3 ml) may be a restrictive factor, especially in cases where limited amounts of
human samples are available.
2.3.4 Saxitoxin
Saxitoxin (STX) is a potent neurotoxin that is produced by marine algae and freshwater
cyanobacteria and it belongs to a group of paralytic shellfish poisoning (PSP) toxins [154-
156]. STX is formed in algal and cyanobacterial cells and it is accumulated in shellfish but it
can also be excreted into the surrounding water [157]. It accumulates in filter-feeding bivalve
molluscs such as mussels, oysters and scallops and therefore can end up in humans or
animals. It is mostly known for causing severe food poisoning when eating shellfish or other
seafood [15]. It is the most toxic PSP variant with an LD50 value of 27.8 nmol/kg by
intraperitoneal injection (i.p.) in mice [158]. STX poisoning is reversible and it blocks the
voltage activated sodium channels, which causes tingling, numbness and weakeness in the
victim. In the worst case, STX causes respiratory failure and death. It is highly lethal and no
antidote is available [2]. STX is also listed in the CWC [5] and it can potentially be used as a
CWA to contaminate food supplies or drinking water in addition to being put into small arms
munitions [159]. Under natural conditions, PSP toxins themselves cause a serious hazard to
public health and a threat to the shellfish industry through the world. Structures of saxitoxin
and the main PSP analogues are listed in Table 6.
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Table 6 Chemical structures of saxitoxin and its main analogues.
Carbamate
Toxins
N-
Sulfocarbamoyl
toxins
Decarbamoyl
toxins
Deoxydecarbamoyl
toxins
OH H
R1 R2 R3 R4 R4 R4 R4
H H H STX GTX 5 (B1) dcSTX doSTX
OH H H NEO GTX 6 (B2) dcNEO -
OH H OSO3- GTX 1 C 3 dcGTX 1 -
H H OSO3- GTX 2 C 1 dcGTX 2 doGTX 2
H OSO3- H GTX 3 C 2 dcGTX 3 doGTX 3
OH OSO3- H GTX 4 C 4 dcGTX 4 -
(dc)GTX = (decarbamoyl)gonyatoxin; (dc)NEO = (decarbamoyl)neosaxitoxin; (dc)STX = (decarbamoyl)saxitoxin;
do(STX) = (deoxydecarbamoyl)saxitoxin; C = N-sulfocarbamoyl toxins
All PSP toxins have the same tetrahydropurine backbone but different functional groups
(Table 6). STX occurs mainly in ionic form and it is stable in acidic conditions but in basic
conditions it oxidizes easily. According to in vivo animal studies, it is excreted from the body
mainly unmetabolized, which is probably due to its high hydrophilicity [160,161]. In some
cases, the post-mortem analysis of the human victims’ bodyfluids and gut contents after
consumption of PSP toxins’ containing crabs, have shown conversions of PSP toxins to
another analogues [162,163]. However, it has also been shown that the detected PSP
analogues had not been converted [164]. In vitro oxidation and glucuronidation have also
been reported [165,166].
The chemical analysis of saxitoxin and its analogues are challenging because of their
highly polar and hydrophilic features. There are no absorptive chromophores in their
structures but with pre- or post-column oxidation it is possible to form aromatic
aminopurine, which can be identified by a fitted fluorescence detector after ion-pair liquid
chromatography (LC–FLD) [167-170]. This method is highly sensitive but it is time-
consuming, fluorescent matrix compounds can interfere with the quantification of other PSP
toxins and for routine monitoring purposes it has a low daily sample throughput [168]. The
LC-FLD methods, enzyme-linked immunosorbent assay (ELISA) and mouse bioassay
(MBA) are currently used for the monitoring of STX in food supplies and drinking water
[171,172]. The latter methods lack specificity, however.
Several studies have shown that hydrophilic interaction liquid chromatography (HILIC)
coupled  with  MS/MS  has  been  suitable  for  the  analysis  of  STX  and  its  analogues  from
various matrices [173-176]. However, the lack of isotopically labeled internal standards for
algal toxins has slowed down the development of validated quantitative analysis methods. In
two studies only, novel 15N7 and 15N4 isotopically labeled saxitoxins have been used as
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internal standards [174,175]. However, these standards are still not commercially available.
In the latest HILIC UPLC−MS/MS (SRM) approach, the quantification of STX and its
analogues were performed by the external standard method [177]. The concentrations of the
toxin analogues that were not present in the external standard solution were determined using
its respective closest structurally related analogue and by using a relative response factor.
Even though the method provided a rapid and sensitive analysis of PSP toxins and optimized
clean-up procedure of various matrices, the quantitation without ISTDs may cause false
results, especially in complex biological matrices.
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3. AIMS OF THE STUDY
The aims of the study were:
· To study in vitro metabolism of selected toxic and incapacitating chemicals by
using various chromatographic and mass spectrometric methods (I-III).
· To screen and identify new metabolites for use as potential biomarkers of
exposure of toxic and incapacitating chemicals using various chromatographic and
mass spectrometric methods (I-III).
· To develop and validate analytical methods for known biomarkers of toxic and
incapacitating chemicals for verification analysis (III-V).
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4. MATERIALS AND METHODS
4.1 Chemicals and reagents
The general chemicals and reagents used in this research are listed in Table 7 and the
reference chemicals are listed in Table 8.
Table 7 Chemicals and reagents.
Compound Manufacturer and purity/grade Study
Acetonitrile (ACN) VWR International, HPLC grade I-IV
Ammonium formate (NH4COOH) Fluka, ≥97% V
Dichloromethane (DCM) Merck, 99.8% III
Dimethyl sulfoxide (DMSO) Lab-Scan, 99.5% I-III
Dithioreitol (DTT) VWR International, >99.5% IV
Formic acid (FA) Merck, 98-100% I-II, IV-V
Glutathione (GSH) Sigma-Aldrich I-III
Methanol (MeOH) VWR International, HPLC grade I
Nicotinamide adenine
dinucleotide phosphate (NADPH)
Sigma-Aldrich I-III
Magnesium chloride (MgCl2) Merck I-III
Potassium phosphate monobasic
(KH2PO4)
Sigma-Aldrich, 99% I-III
Potassium diphosphate dibasic
(K2HPO4)
Sigma-Aldrich, 99% I-III
Water (resistivity 18.2 mW) Elgastat option3A and UHQ PS equipments (Elga)
Direct-Q3 UV equipment (Millipore) 
II, IV-V
I, III
Table 8 Reference chemicals.
Compound Manufacturer and purity/grade Study
MSMTESE VERIFIN, purity >95%* I, V
SBMSE VERIFIN, purity >95%* I, V
D6-SBMSE VERIFIN, purity >95%* I
Capsaicin Sigma-Aldrich, ≥95% II
Chloropicrin Fluka, 99% III
Dihydrocapsaicin Sigma-Aldrich, ≥85% II
Gonyautoxin 5 NRC, Certified Reference Materials Program V
Nitromethane Sigma-Aldrich, 98.5% III
15C-Nitromethane Sigma-Aldrich, 99 atom % 15C III
D3-Nitromethane Sigma-Aldrich, 99 atom % D III
Saxitoxin NRC, Certified Reference Materials Program V
Sulfur mustard Finnish Defence Research Agency I
Sulfur mustard oxide Finnish Defence Research Agency I
* Synthesized by VERIFIN, according to previously published method [178].
Purity determination was conducted by 1H NMR and LC−MS analyses (unpublished data).
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4.2 Biological sample matrices
Various sample matrices from biological origin were used in this research and their details
can be found in studies I-V.
In vitro exposure studies were performed using pig liver samples obtained from
untreated female pigs that had been used for practicing surgical procedures in the University
of Eastern Finland (I-III). These liver microsomes were prepared from the animals as
described previously by Lang et al. [179] and the experiments were approved by the Ethics
Committee for Animal Experiments. Human liver samples were obtained either from patients
undergoing surgery to remove hepatic tumors [180] (I) or from tebu-bio (Roskilde,
Denmark) prepared from liver cell fractions pooled from 10 donors (II, III).  The  use  of
surplus tissue was approved by the Ethics Committee of the University of Eastern Finland.
Human lung cell line (A549) was obtained from American Type Culture Collection (ATCC,
CRL-2302TM, USA) (II).
Freeze-dried blank dinoflagellate samples from the Baltic Sea and cultured Alexandrium
Ostenfeldii samples taken from algal strains AOTV-A4/3 and AOTV-B4/6 from Föglö,
Åland were obtained from Finnish Environment Institute (IV).
Pooled  urine  from  four  healthy  human  subjects  was  used  in  the  development  of  the
respective method and its validation, and the method was evaluated by using samples from
the first confidence building exercise for biomedical sample analysis that had been prepared
in artificial urine by the TNO Laboratory (V).
4.3 Sample preparation
4.3.1 In vitro exposures
Human and pig liver microsomal and cytosol fractions were used as an enzyme source in the
in vitro exposures.  The  amount  of  the  enzyme  was  1  or  2  mg  protein/ml  in  the  reaction
mixtures. In addition, the reaction mixture contained generally 0.25 mM NADPH and 5 mM
GSH in 100 mM potassium phosphate buffer with 3.3 mM MgCl2 at pH 7.4.
Variable concentrations of the substrates i.e. the studied chemicals were used and the
substrate was always diluted into DMSO. Final volumes of the reaction mixtures were either
0.5 ml or 1 ml, and the incubations were performed at 37 ºC. The reactions were started by
addition of the substrate into the reaction mixture and were terminated after varied time
periods had elapsed by the addition of cold ACN. After termination, the samples were mixed
by a vortex mixer, and centrifuged for the removal of the precipitated proteins. Supernatants
were analyzed directly by LC−MS/MS, and after heating when analyzed by the HS−GC−MS
method.
Cell culture medium, from exposed human lung cell (A549) culture samples, was
extracted with DCM to remove the extensive background of culture medium. The extract
was evaporated and diluted into LC−MS eluent prior analysis. The detailed composition and
preparations of the reaction mixtures are presented in studies I-III.
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4.3.2 Algae samples
Cultivation, collection upon filter papers and freeze-drying of algae were conducted at the
Finnish Environment Institute [181]. Freeze-drying was conducted for rupturing the cells and
minimizing the liquid water content in the samples. The freeze-dried samples with filter
papers were wetted in large vials with analysis buffer mixture added, then shaken roughly,
and allowed to stand in ice and then centrifuged. Then the samples were filtered through
centrifuge filters. Three different centrifuge-filters were tested for sample preparation;
PVDF (0.45 µm), PTFE (0.2) µm and YM-3 (molecular cut-off 3 kDa). Recovery samples
were spiked with saxitoxin and the respective ISTD just after addition of extraction solvent
and before filtering. The detailed sample preparation of algae samples is described in
study IV.
4.3.3 Urine samples
Urine samples (0.5 ml) were purified by using SPE cartridges to remove potentially
disturbing matrix components. Strata-X SPE cartridges (polymeric reversed phase) were
tested at first and discarded, since it retained only MSMTESE. Then ENV+ SPE cartridges
(hydroxylated polystyrene-divinylbenzene copolymer) were used according to previous
study and the conditioning and washing solutions were optimized for a smaller cartridge
(25 mg/1 ml). All solutions contained also 0.05% of formic acid to improve the
chromatographic peak shape and to reduce the pH of the buffered samples. The dithioreitol
(DTT) was added into the conditioning solvent to prevent oxidation of MSMTESE to
SBMSE as described by Read and Black [91]. Both target chemicals, SBMSE and
MSMTESE, were eluted in the same fraction. Eluates were evaporated to an approximate
volume of 0.5 ml. The more detailed sample preparation of urine samples is described in
study V.
4.4 Instrumentation and equipment
LC−MS/MS and GC−MS instruments that were used in this study are listed in Table 9 and
all the other equipment including chromatography columns and SPE cartridges are listed in
Table 10. The detailed information of used LC−MS and GC−MS methods are in studies I−V.
Table 9 LC−MS/MS and GC−MS instrumentation used in the studies I-V.
LC or GC MS Publication
Accela HPLCa
Surveyor Plus HPLCa LXQ Linear ion trap MS
a I, II
IV, V
Acquity UPLCb Q-TOF Xevob I
Accela HPLCa TSQ Quantum Ultra triple quadrupolea II, V
Dionex Ultimate 3000 UHPLCa Orbitrap Fusiona II
GC 6890Nc Single quadrupole MS 5975Bc III
aThermo Scientific; bWaters; c Agilent
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Table 10 Other equipments used in the studies I-V.
Equipment Manufacturer and model Publication
Gastight syringe Hamilton III
Centrifuge and rotor Thermo Scientific/Heraeus multifuge X1R,
Thermo Scientific Fiberlite F15-6x100y rotor
Eppendorf R5810R, Eppendorf  F 45-30-11 rotor
I, II
IV
Centrifuge filter Millipore, Ultra free MC Duvapore PVDF IV
Evaporator Caliper Lifesciences, TurboVap® II I-II, V
GC column Agilent, J&W DB5-MS III
Heating block Labnet, Accublock
ThermoCell mixing block (MB-102)
III
I, II
HILIC columns TOSOH Bioscience, TSK-gel Amide-80®
Waters, HILIC Silica
IV
LC C18 columns Agilent, UHPLC SB-C18
Waters, XBridge C18
I, V
I, II
pH meter Meter Toledo, MP225
Postcolumn splitter Norlab, ASI
Norlab, LC Packings
I, II
IV, V
SPE cartridges IST, ENV+
Phenomenex, Strata-X
V
SPE manifold Baker-SPE 12 G V
4.5 Validation performance
During this study, three chromatographic and mass spectrometric bioanalytical methods were
validated. Despite the variability of the instrumentation, the same validation platform of the
appropriate FDA guidance was used for the relevant parts [55]. Validation runs were
performed at three (III)  or  four  consecutive  days  (IV,  V). Three calibration curves were
obtained per day during three days (n = 9) and all the standards were prepared in the same
matrix as the target samples and were subjected to the same sample preparation procedure as
the target samples; pre-heating (III), liquid extraction (IV)  or  SPE  treatment  (V). The
recovery tests were analyzed on the fourth day (IV, V).
Internal standard calibration was used for all validated methods and of these two were
with stable isotope labeled (III, V)  and  one  with  structural  analog  (IV). Data acquisition
methods were SIM (III), MS/MS by following four specific product ions (IV) and SRM by
following two fragmentation reactions (V). All the quantitative results were calculated from
the integrated areas of the extracted ion chromatograms (EICs).
True values for concentrations of calibration standards and their accuracy (relative
standard deviation, RSD) were calculated from the nine calibration curves. Precision
(variance within group and between groups), random error, systematic error (bias) and
combined uncertainty were calculated from the calibration standards’ true values. Single-
factor Analysis of Variance (ANOVA) was used to calculate these validation results.
Linearity was assessed from residual plots and from the correlation coefficients of all nine
calibration curves. The residuals are differences between the observed values and the
calculated values. When the points in the residual plot are randomly dispersed around the x-
axis, it indicates a good fit for a linear model.
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The selectivities of the methods were tested using matrix blanks and purified water
during the validation. LOD and lower LOQ were calculated using equations presented in
studies IV and V. Ratios between the qualifier (q) and quantifier (Q) ions or transitions were
calculated from peak areas of EICs which eliminate the risk of false positive results and
compared to the WADA criteria (Table 3). Validated methods were also evaluated using the
WADA and the OPCW identification criteria [57,58].
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5. RESULTS AND DISCUSSION
5.1 In vitro metabolite screening and identification
The first objective of this research was to study the suitability of the conventional in vitro
model to determine the metabolic fate of selected toxic and incapacitating chemicals. The
knowledge of the metabolism of sulfur mustard has been previously assessed from in vivo
animal models and human casualties, in addition to the in vitro experiments that used blood
that had been developed. However, the hepatic in vitro metabolism of sulfur mustard had not
been studied previously. Information of hepatic in vitro metabolism for capsiacinoids was
available but it had not assessed from the pepper spray exposure point of view. In addition,
information on dihydrocapsaicin was lacking, and dihydrocapsaicin is the second most
abundant component in pepper spray products. The knowledge of in vitro and in vivo
metabolism about chloropicrin is limited.
Several human and pig hepatic subcellular fractions (I-III) and a human lung cell line
(A549) (II) were used to assess the phase I and II metabolic reactions. The in vitro
metabolites of sulfur mustard (I) and capsaicinoids (II) were screened by LC−MS methods,
whereas nitromethane, a metabolite of chloropicrin, was detected by HS−GC−MS because of
its high volatility and low molecular weight (III).
A conventional C18 column and gradient elution were chosen to separate the metabolites
in the LC−MS analyses and the metabolites were screened using full scan (I, II) and
precursor ion scan modes (II). Identifications of the found metabolites were performed
mainly by MS/MS, MS3 and  by  accurate  mass  measurements  (I, II). Ionization was
conducted by ESI, since some analytes and formed conjugates were observed to break down
under APCI conditions.
5.1.1 Phase I metabolism
5.1.1.1 Sulfur mustard
Sulfur mustard is quickly and spontaneously hydrolyzed to TDG in an aqueous environment,
and further oxidized to TDGO, especially in basic conditions. Its reactivity is based on the
formation of episulfonium ion, reactive intermediate (see Figure 1). There are only a limited
number of positions in the molecule where metabolic reactions can occur, due to the
chemical structure of sulfur mustard.
The in vitro experiments were performed at physiological pH 7.4 and TDG or TDGO
were not detected. However, S-oxidized sulfur mustard, HDO, was detected in both the
human and pig cell fractions by full scan MS screening mode with precursor ion at m/z 175.
Several fragment ions of HDO were identified in the MS/MS spectrum. The fragment ions at
m/z 147 and m/z 113 are probably formed after the elimination of ethane (-28 Da) and
chloroethene (-62 Da), respectively. The MS/MS spectra and proposed interpretation of
whole fragmentation of HDO are shown in Figure 5.
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Identification was confirmed with analysis of reference chemical and comparison of
their retention times and mass spectra (see study I). There is no previously published
LC−MS/MS spectrum of HDO available to our knowledge. HDO was found to be abundant
in the microsomal incubations and it was the main metabolite in biological control samples
for which GSH had not been added. Minor amounts of this metabolite had also been detected
after incubation with bare cytosol fraction in both species. Since HDO was not detected in
chemical control samples, it could be assumed that this metabolite has only been produced
by enzymatic reactions. The oxidizing enzymes could be some of the cytochrome P450
enzymes or flavine monooxygenases, which are known to oxidize a number of sulfur
containing substrates [182]. Recently, HDO was found in patient’s plasma after an accidental
exposure  to  sulfur  mustard  and  HDO  may  thus  be  considered  to  be  a  biomarker  of  the
exposure [95].
Figure 5 MS/MS spectra of the in vitro sample (panel A) and reference chemical (panel B) of HDO
with proposed interpretation fragmentation (I).
5.1.1.2 Capsaicinoids
Among the studied chemicals, the structure of capsaicinoids is the closest to the general drug
molecules and contains several positions for phase I metabolic reactions. The hepatic in vitro
metabolism of CAP has already been comprehensively studied [128,129], therefore the
comparison of the in vitro metabolism of CAP and DHC, two of the most abundant
components in pepper spray products, were assessed using both hepatic subcellular fractions
and human lung cell culture (A549). Both CAP and DHC were metabolized extensively by
oxidative metabolic reactions. The metabolic alterations into the alkyl chain were first
detected in the precursor ion scan mode by QqQ by using the typical fragment of the vanillyl
moiety (m/z 137) of the capsaicinoids (Figure 6). Full MS and MS/MS scans were performed
by the ion trap instrument.
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Figure 6 Total ion chromatogram (TIC) and combined extracted ion chromatograms (EIC) of the
precursor ion scan (m/z 137) of human in vitro sample, exposed to 100 µM of capsaicin.
Precursor ions of m/z 294, m/z 304, m/z 306 (capsaicin) and m/z 322 were detected.
Phase I metabolic alterations detected by precursor ion scan were identified by linear ion
trap as aliphatic dehydrogenation (macrocycle), w-hydroxylation, w-1-hydroxylation and
aliphatic dehydrogenation (Figure 3). The MS/MS spectra of these structures have previously
been reported for only CAP [128] but in this study MS/MS spectra were also reported for
DHC (see study II). In addition, proposed O-demethylated metabolite ([M+H]+ 294) and
novel metabolite with aliphatic hydroxylation ([M+H]+ 322) were detected in DHC but no
corresponding structures were found in CAP. Further confirmation of these novel structures
in DHC should be performed, however. All the found phase I metabolites for DHC and their
MS/MS spectra with proposed interpretation are presented in Figure 7.
A novel phase I metabolite that corresponded to aliphatic demethylation and
dehydrogenation ([M+H]+ 294) was identified for CAP. The fragments in MS/MS spectra of
this metabolite were m/z 137, 158 and 170, which corresponds the fragmentation of vanillyl
portion and alkyl chain at two different positions, respectively.
m/z 304
m/z 304
m/z 322
m/z 322 m/z 294
m/z 306
Capsaicin
TIC
EIC
39
Figure 7 MS/MS spectra with proposed structures and interpretations of the phase I metabolites of
dihydrocapsaicin found in hepatic in vitro samples (II).
The phase I oxidative metabolism in the A459 cells as expected was found to be weaker
than in the liver fraction, additionally only the following were identified from the cell culture
media: w-hydroxylated ([M+H]+ 322) and alkyl dehydrogenated ([M+H]+ 304) for CAP, and
alkyl dehydrogenated ([M+H]+ 306) and novel alkyl hydroxylated ([M+H]+ 322) for DHC.
The phase I metabolites found in human liver subcellular fractions were similar to those
found in the pig corresponding fractions. The formation of metabolites was concentration
dependent to some extent. For example the macrocycle, w-hydroxylated, novel alkyl
hydroxylated metabolites were found in the samples, in which initial concentrations of CAP
or DHC were 10 µM. Furthermore, the w-1-hydroxylated metabolites ([M+H]+ 322 and
[M+H]+ 324) were detected only when initial concentration of CAP or DHC was 100 µM
and when both microsomal and cytosol fractions were present in the incubation mixture. The
effect of the incubation time was slight and all the metabolites in 100 µM incubations were
formed almost immediately after spiking and had reached their peak concentrations within
30  minutes.  All  the  samples  also  contained  unmetabolized  CAP  or  DHC,  but  these
concentrations decreased with increasing incubation time.
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5.1.1.3 Chloropicrin
Chloropicrin was previously reported to form nitromethane via dechlorination in a study on
mice that used in vitro and in vivo approaches [150] and also in a study that used in vitro
human blood [36]. In the present study III, human and pig hepatic subcellular fractions were
used to investigate the formation of nitromethane. A validated HS−GC−MS method (see
Chapter 5.2.3) was used to detect and quantify nitromethane.
Two sets of in vitro samples were exposed to chloropicrin, and approximately 11.0 µM
(0.7 µg/ml) of nitromethane was detected after one hour of incubation in one sample in the
first set in which the human S9 fraction was used. This incubation was exposed to 100 µM
chloropicrin (16.4 µg/ml) and it was the only incubation sample that had GSH added among
the first sample set. This result indicated a requirement for GSH for the formation of
nitromethane from chloropicrin.
The second sample set contained both liver cytosol and microsomal fractions together or
separately, and more nitromethane was formed from the chloropicrin in the cytosol than was
found in the microsomal fractions. The highest concentration 35.8 µM (2.2 µg/ml) of
nitromethane  was  formed  in  the  pig  cytosolic  sample,  which  was  exposed  to  100  µM
(16.4 µg/ml) of chloropicrin. The amount of nitromethane that was formed in the
corresponding human cytosol sample, was less than one-fifth (6.0 µM, 0.4 µg/ml) of the
concentration in pig cytosolic fraction. The lowest concentrations of nitromethane were just
at  the  LOD  level  and  were  found  in  two  samples,  which  had  either  been  exposed  to  the
lowest concentration of chloropicrin (10 µM) or were without the enzyme fraction. Only one
time point (an hour) was used in this study and it is possible that within more time, the
nitromethane concentrations would get higher. More detailed results of in vitro samples are
presented in study III.
The results indicate that formation of nitromethane from chloropicrin is dependent on the
reduction potential e.g. the concentration of GSH in the reaction mixture. This release of
chlorine from chloropicrin may be direct and spontaneous reaction or it may be catalyzed by
various cytoplasmic enzymes. The release of chlorine is probably an important factor in the
toxicity of chloropicrin [149]. The more pronounced formation of nitromethane in cytosolic
fraction than in microsomal fraction in this study may be explained by the higher reducing
potential of the cystolic fraction [183]. These in vitro results support those of previous
studies where nitromethane and cyclic cysteine adduct (raphanusamic acid) were detected
from chloropicrin exposed mice [150,151].
5.1.2 Phase II metabolism
5.1.2.1 Sulfur mustard
Three GSH conjugates of sulfur mustard were detected from the in vitro samples using the
full MS scan mode. Identification of bis(2-(S-glutathionyl)ethyl)sulfane (bi-conjugate), and
novel 2-((2-(S-glutathionyl)ethyl)thio)ethanol (mono-conjugate) were conducted by MS/MS
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using  precursor  ions  at m/z 412 and m/z 701, respectively. The third GSH conjugate was
identified as a novel 2-((2-(S-glutathionyl)ethyl)thio)ethyl phosphate (phosphate conjugate)
by MS/MS using a precursor ion at m/z 492. The detected GSH conjugates were identified by
neutral loss of pyroglutamic acid (-129 Da) in MS/MS spectra, which is a typical
fragmentation reaction for GSH conjugates. Typical isotope pattern of several sulfur atoms
were also detected from the MS spectra of GSH conjugates.
MS3 were  performed  for  all  three  GSH  conjugates  using  a  linear  ion  trap  MS  for
structural characterizations. The most abundant product ions in MS/MS spectra were chosen
for  precursor  ions  in  MS3 scans at m/z 283, m/z 443, and m/z 394 for mono-, bi- and
phosphate conjugate, respectively. Fragmentations obtained from MS3 scans matched the
proposed structures. Figure 8 shows the proposed structures of all identified GSH conjugates
and their MS/MS and MS3 spectra with proposed fragmentations. More detailed
interpretations of these spectra have been proposed in the Supporting Information of study I.
The samples were also analyzed by the UPLC−TOF-MS method to measure the accurate
masses of all three GSH conjugates and confirm their elemental composition, because no
reference chemicals were available. The GSH conjugates were detected at m/z 701.1941,
m/z 412.1218 and 492.0871, respectively. Precursor ions measured by the UPLC−TOF-MS
in addition to the calculated errors that were compared to the exact isotopic masses are given
in Table 11. The results support the structures proposed in Figure 8.
Table 11 Measured precursor ions of GSH conjugates with their errors compared to the exact
isotopic masses and proposed elemental composition (I).
Conjugate Measured mass[M+H]+
Error
(mDa)
Error
(ppm)
Proposed
composition
Bi-conjugate 701.1941 -0.3473 -0.5 C24H41N6O12S3+
Mono-conjugate 412.1218 0.6107 1.5 C14H26N3O7S2+
Phosphate-conjugate 492.0871 0.4552 0.9 C14H26N3O10S2P+
The GSH conjugates were not found in the matrix blanks nor in the biological controls
without added GSH, however they were detected in the chemical control samples that
contained just sulfur mustard, buffer and GSH. The same control samples were prepared in
purified water to investigate the effect of the solution on the conjugation reaction. No
conjugates were detected from them, just TDG.
The GSH conjugation of sulfur mustard occurred rapidly since the conjugates were also
detected in the zero-time-point sample. Since there was no detectable TDG in the buffered
samples, the conjugation with GSH seems to be a faster reaction than hydrolysis, if there is
GSH available. The GSH conjugation probably also occurs without enzymes in physiological
salt and pH conditions. Buffered solution conditions might also delay the hydrolysis
reactions and maintain the native sulfur mustard molecule longer thus enhancing its
availablity for conjugation reactions. These observations support the fact that GSH derived
metabolites (e.g. b-lyase metabolites) are the main urine metabolites found after sulfur
mustard exposure. The bi-conjugate structure was reported to be further metabolized by b-
lyase enzymes to form b-lyase metabolites [65].
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Figure 8 Proposed structures of identified GSH conjugates of sulfur mustard and their MS/MS and
MS3 spectra with proposed interpretation of fragmentation (see study I). A) bi-conjugate,
B) mono-conjugate, C) phosphate-conjugate.
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The amounts of bi-conjugate in all samples were clearly lower than the mono-conjugate
and phosphate conjugate. The reason why the sulfur mustard molecule was partly hydrolyzed
prior to full GSH conjugation is unknown, since there was a surplus of GSH in the reaction
mixture. The phosphate conjugate could be the result of hydrolysis with phosphate
substituents of the phosphate buffer. These novel GSH conjugates could in theory be formed
in humans in vivo after exposure to sulfur mustard because phosphate is an important and
ubiquitous endogeneous component of human fluids and tissues. Most probably all of the
non-oxidized sulfur mustard was conjugated with GSH during the incubations and no intact
chemical was left, due to the rapidity of the reactions.
The  amounts  of  conjugates  in  some  samples  were  a  little  lower  after  two  hours  of
incubation than after one hour. This might indicate that the metabolic reactions could have
possibly gone further but the amounts of the metabolites were so low after two hours they
were not detectable in MS full scan mode. The b-lyase metabolites of sulfur mustard were
screened by MS/MS but they were not detected.
Full scan mass spectra were screened using masses of the hypothetical intermediate
structures between GSH conjugates and b-lyase metabolites. However, no other products that
suggested further metabolism were detected. This could indicate that either a time interval
longer than two hours for the b-lyase reactions might be required or that the content of
special enzymes for b-lyase reaction were too low in the cell fractions. In addition, it was
suggested that these metabolites could be formed in the kidney [95] and would need various
subcellular fractions and possibly other co-factors to proceed.
5.1.2.2 Capsaicinoids
Three GSH conjugates were detected in full MS scan for both CAP and DHC and the three
conjugates were further identified by MS/MS and MS3. These metabolites were formed after
O-demethylation and GSH conjugation ([M+H]+ at m/z 597 and m/z 599), after solely GSH
conjugation ([M+H]+ at m/z 611 and m/z 613), and after aromatic hydroxylation and GSH
conjugation ([M+H]+ at m/z 627 and m/z 629) of CAP and DHC, respectively. The structures
and  spectra  of  these  GSH  conjugates  of  capsaicin  are  in  line  with  the  previous  study  by
Reilly et al. [129]. The previously unpublished MS/MS spectra of GSH conjugates of DHC
with proposed interpretation are presented in Figure 8.
Novel glycine conjugates ([M+H]+ at m/z 363 and m/z 365) and bi-GSH conjugates
([M+H]+ at m/z 902 and m/z 904), were also identified for both CAP and DHC. The MS/MS
spectra of glycine conjugates contained the same product ion at m/z 194 for both CAP and
DHC. This indicates that the metabolic alteration occurred in an aromatic part of the
molecule since the typical fragment ion of unattached vanillyl portion (m/z 137) was missing
from the spectrum. The observed fragment ion at m/z 194 corresponded to the proposed
structure of glycine conjugated with a vanillyl portion where the conjugation with the
hydroxyl group takes place. An MS3 scan revealed a fragment ion at m/z 179, which
corresponds to the loss of ammonia from the glycine residue.
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Novel  bi-GSH  conjugates  of  CAP  and  DHC  were  first  observed  as  double  charged
molecules [M+2H]2+ at m/z 451 and 452, respectively, since these were the most abundant
peaks in their full scan MS spectra. The outcome of this is that the mass difference between
the two novel bi-GSH conjugates was only 1 amu and then the conjugates yielded only half
of the mass of the typical neutral loss of pyroglutamic acid (-129 Da→ -64.5 Da). However,
the [M+H]+ at m/z 902 and m/z 904 for bi-GSH conjugates of CAP and DHC, respectively,
were  also  detected  in  small  amounts  and  the  fragments  formed  in  the  MS/MS  scans
contained typical neutral losses of GSH conjugates. These were losses of NH2CH2COOH (-
75 Da) and pyroglutamic acid (-129 Da) and the losses for both fragments occurred twice.
Interpretation of the fragments revealed the GSH conjugations had to have occurred within
the phenyl ring and with the carbon between the ring and the amide bond in the alkyl chain.
In addition, the O-demethylation had also occurred. Figure 9 shows the MS/MS spectra of
detected conjugates for DHC with proposed interpretation.
Figure 9 MS/MS spectra of identified conjugates of dihydrocapsaicin with proposed interpretation.
A) Glycine conjugate, B-D) GSH conjugates, E) bi-GSH conjugate (II).
The structures of the GSH conjugates were also successfully confirmed by accurate mass
measurements using the UHPLC−Orbitrap-MS configuration. Measured precursor ions and
the calculated errors compared to exact isotopic masses are given in Table 12.
Both low (10 µM) and high (100 µM) concentrations of CAP and of DHC produced
GSH conjugates and glycine conjugates in human and pig hepatic subcellular fractions
(microsomes and cytosol). Only the novel glycine conjugates were detected in the phase II
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metabolites of the extracted media of the exposed human lung A459 cell culture. The novel
glycine conjugate found in this study is interesting from the pepper spray exposure
perspective. Its use as a possible biomarker for pepper spray exposure should be further
confirmed and evaluated.
Table 12 Measured precursor ions of GSH conjugates of dihydrocapsaicin, their errors compared to
the exact isotopic masses and proposed elemental composition (II).
Conjugate
[M+H]+
 (calc.)
[M+H]+
(anal.)
Error
(mDa)
Error
(ppm)
Proposed
composition
GSH conjugate (O-demethylated) 599.27508 599.27598 0.90 1.50 C27H43N4O9S+
GSH conjugate 613.29073 613.29037 -0.36 -0.59 C28H45N4O9S+
GSH conjugate (hydroxylated) 629.28564 629.28558 -0.06 -0.10 C28H45N4O10S+
bi-GSH conjugate (O-demethylated) 904.34268 904.34308 0.40 0.44 C37H58N7O15S2+
5.2 Quantitative method development and validation
The second objective of this research was to develop and validate analytical methods for
known biomarkers of selected toxic and incapacitating chemicals for verification analysis.
These biomarkers included b-lyase metabolites of sulfur mustard (V),  saxitoxin  (IV) and
nitromethane as a metabolite of chloropicrin (III). Biomedical sample analysis could be the
only feasible option to verify the illegal use of these chemicals in litigation or criminal
proceedings: especially in those cases for which environmental decontamination measures
have already been conducted. The analyses methods therefore must be highly sensitive and
selective, in addition to the requirement for meticulous biomedical sample collection,
transportation and storage, since the biomarkers are mainly present only at the trace level in
biomedical samples.
Since the 2010, several confidence building exercises for biomedical sample analysis
have been arranged by the OPCW. The purpose of these exercises has been to build up
expertise in the preparation and accurate analysis of biomedical samples that are relevant to
the investigation of alleged use. The results from the first exercise concerning the b-lyase
metabolites are presented and evaluated (V).
The general bioanalytical method validation guidance from the FDA [55] and
identification criteria from the WADA [57] and OPCW [58,184] have been used in this
research and their suitability for verification analysis is discussed. More detailed information
can be found in studies III-V.
5.2.1 Sample preparation and recovery results
The b-lyase metabolites of sulfur mustard are mainly detected in urine samples within a
period of less than two weeks after exposure [91] therefore the sample preparation method
must be selective and also obtain good recovery. Two different SPE cartridges were
evaluated for extraction of b-lyase metabolites in this study. Pooled human urine from
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healthy  volunteers  was  used  as  a  matrix  to  provide  a  realistic  background  for  the
measurements. The optimized SPE conditions enabled the use of smaller SPE cartridge and
sample amounts (0.5 ml) in addition to lower solvent consumption than in the previously
published method by Read and Black [91]. The small sample amount used was to mimic a
more realistic situation in which only limited amounts of sample would be available from
casualties.
The recoveries of the b-lyase metabolites were determined by spiking six (n=6) parallel
samples at three concentration levels of 5, 50 and 200 ng/ml, which follows the FDA
guidance. The mean recovery was near or even over 100% for both analytes, which indicates
high extraction efficiency and also some matrix effect. The FDA guidance stipulates that the
recovery of the targeted analyte need not be 100% but it should be consistent, precise and
reproducible. The RSD’s of the recovery results in our study were only from 2% to 5% and
3% to 11% for SBMSE and MSMTESE, respectively. The SPE recovery results for b-lyase
metabolites are fully presented in study V.
Saxitoxin is the only chemical in this research that was analyzed in its intact form. The
extraction method was developed for verification purposes when it was first used to analyze
algae samples in which the concentrations in the cells were higher than in water or in
biomedical samples. STX and the ISTD (GTX 1) were extracted from the freeze-dried algae
samples with acidic solution that contained ammonium formate buffer at pH 3.5 and ACN
(see Chapter 4.3.2). Three different centrifuge-filters were tested for their ability to remove
the impurities and algal cell remains of the sample to evaluate their suitability for sample
preparation. The YM-3 filter turned out to be too thick due to the long centrifugation time
and it also had a poor recovery. Quite similar results were obtained with the PVDF and PTFE
filters, however the PVDF was chosen for further validation studies, since the PTFE filters
seemed to have a slight absorbtion effect.
The recovery of STX was determined by using three parallel samples (n=3) for each of
two concentration levels of 10 ng/ml and 200 ng/ml due to the limited amount of STX-free
algal matrix (Table 13). This does not fulfil the FDA recommendations of six parallel
samples and three concentration levels but it did give a reasonable picture of the extraction
efficiency. The recoveries of 10 ng/ml samples were calculated from a calibration range of 5-
50 ng/ml and the 200 ng/ml samples from a calibration range of 25-200 ng/ml, since linear
calibration was not possible within the whole range due to the the ion suppression and
bending of the calibration curves. However, linear calibration was later achieved by raising
the MS capillary temperature. Yet, since the calibration curves have tendency to bend for the
ion suppression, it would be recommended that sample containing 200 ng/ml or more of
saxitoxin should be diluted and re-analyzed to get most reliable quantitative results.
Table 13 Recovery of saxitoxin from spiked algal matrix (IV).
Concentration Recovery samples Mean recovery SD RSD (%)n= 1 n= 2 n= 3
10 ng/ml 100.6% 97.3% 101.7% 99.9% 2.3% 2.3%
200 ng/ml 123.6% 106.1% 105.3% 111.7% 10.3% 9.2%
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Nitromethane was analyzed using the HS method due to its high volatility. The HS
analysis is based on the partitioning of a volatile analyte between the sample phase (liquid)
and headspace (gas) and it does not require any derivatization or solvent exchange. The
tendency of the analyte to separate more readily into the headspace could be increased by
raising the temperature of the sample, which also improves the sensitivity.
Aqueous samples in this study were therefore heated in a heating block and water was
added to the wells of a heating block to improve the heat transfer. The effect of heating was
studied at three time points (10, 15 and 20 min) and at three temperatures (70, 75 and 80 ºC)
at three nitromethane concentrations of 2, 3, 4 µg/ml (see Supporting Information of
study III). The lowest temperature of 70 ºC for 20 min was selected as the optimal
experimental conditions since water was found to evaporate readily from the wells of the
heating block at higher temperatures. A conventional recovery test was not applied since
there  was  no  sample  preparation  step  in  this  method (except  the  addition  of  ISTD into  the
samples).
5.2.2 LC−MS/MS analyses
5.2.2.1 SRM method for b-lyase metabolites
LC conditions were optimized for b-lyase metabolites of sulfur mustard before validation to
achieve the best chromatographic peak shapes, the highest resolution and to attain as fast
analysis as possible. Retention times under the final optimized conditions were
1.96 ± 0.01 min and 3.24 ± 0.03 min for MSMTESE and SBMSE, respectively, which was
shorter retention times than those previously published for the method by Read and
Black [91]. The deuterated ISTD (D6-SBMSE) eluted approximately same time as the
SBMSE. During the validation, differences in retention times were at the maximum ±
0.03 min or 0.9%, which follows the WADA criteria of retention times [57]. Two SRM
transitions for each of SBMSE, MSMTESE and D6-SBMSE were chosen for the validation
based on preliminary full MS scan and MS/MS experiments (see study V). The selectivity of
the method was also tested with blank samples of SPE treated human urine and purified
water during the validation. No interferences or analytes were observed in the blank samples.
The mean q/Q ratios of the validation samples were calculated and results compared to
the WADA criteria [57] (see Table 3). The mean ratios were 54% for SBMSE and and 12%
for MSMTESE in the validation samples. Some ratios for SBMSE were under 50% but the
mean ratio was over 50% (n=54) and then the absolute difference could be at the maximum
± 10%. The absolute difference calculated was 9.3% and relative difference was 17.4%, both
of which fulfil the WADA criteria. The q/Q ratio for MSMTESE was between 5% and 25%,
and the absolute difference could be only ± 5% according to WADA. The calculated absolute
difference was 1.8% for MSMTESE, which is good and acceptable.
Validation samples prepared in pooled human urine gave linear calibration curves over
the range of 5-200 ng/ml for both b-lyase metabolites. S/N ratios of quantifier reactions were
always higher than twenty-to-one (20:1) which met the WADA criteria. The method was
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proved to be accurate and precise according to the calculated results, which were combined
in study V. The RSD values for SBMSE were under 4% except for the lowest concentration
level for which it was 10.8%. The RSD values for MSMTESE were also under 4% except for
the two lowest concentrations, which were 10.8% and 22.9%, respectively. The variances
within group for the SBMSE were under 6% except at lowest concentration. The variances
between groups were insignificant. The corresponding values for MSMTESE were higher
but still under the FDA guidance levels. The combined uncertainty that describes all the
uncertainty values summed together for each concentration levels were also calculated. Most
of the values follow the FDA guidance. Some slight differences in validation results between
SBMSE and MSMTESE are maybe a consequence of using only one ISTD, D6-SBMSE. In
addition, because of the use of ISTD, the observed systematic error was insignificant. LOD’s
and LOQ’s for SBMSE were 4 ng/ml and 10 ng/ml, and for MSMTESE 4 ng/ml and 11
ng/ml that were calculated using equations presented in study V.
The validated method for b-lyase metabolites was used in the first confidence building
exercise for biomedical sample analysis, arranged by the OPCW. Two of the seven exercise
samples contained SBMSE at concentration levels of 10 and 100 ng/ml. SBMSE was
successfully quantified using the validated method from both samples at 13 ng/ml ( ±18.6%)
and 91 ng/ml ( ±4.9%) using combined uncertainty. In this exercise, real human urine was
spiked with SBMSE as the reference samples and then SPE treated in parallel with the
exercise samples.
In the exercise samples, the mean q/Q ratio for a reference standard of SBMSE was
47.4% (n=2) being under 50%. The area ratio of the reference standard was compared to
same area ratios of exercise samples in both absolute and relative terms (Table 14). The
absolute and relative differences in retention times were also calculated. The differences
between area ratios vary depending on the peak ratio and calculation type (i.e. whether
absolute or relative). According to WADA criteria, the relative difference should not been
more than ± 20% when the q/Q ratio is between 25-50%. In our study only one sample
(sample s7c/05) should have been either reanalysed or the result should have been discarded.
Table 14 The results from the first confidence building exercise for biomedical sample analysis (V).
Chemical Description Rt(min)
Δ Rta Relative
Abundance Δ Relative Area
b
Absolute Relative (% of q/Q) Absolute Relative
SBMSE
100 ng/ml
Ref 100 ng/ml 2.01 – – 47.8% – –
Sample s5a/05 2.01 0.00 0.0% 44.2% -3.6% -7.5%
Sample s5b/05 2.02 +0.01 0.5% 46.8% -1.0% -2.1%
Sample s5c/05 2.02 +0.01 0.5% 45.2% -2.6% -5.4%
SBMSE
10 ng/ml
Ref 10 ng/ml 2.01 – – 47.0% – –
Sample s7a/05 2.00 -0.01 -0.5% 39.0% -8.0% -17.0%
Sample s7b/05 2.02 +0.01 0.5% 43.7% -3.3% -7.0%
Sample s7c/05 2.02 +0.01 0.5% 32.2% -14.8% -31.5%
a Difference in retention time
b Difference in relative area (q/Q ratio)
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5.2.2.2 HILIC−MS/MS for Saxitoxin and its analogues
The optimal chromatographic separation and peak shapes for STX and its main analogues
(neosaxitoxin, decarbamoylsaxitoxin, decarbamoylneosaxitoxin, gonyautoxins 1-4, N-
sulfocarbamoyltoxin 5 and decarbamoylgonyautoxins 1 and  2, see Table 6) were achieved
during extensive method development work, which was perfomed before the validation
studies. More detailed information can be found in study IV. Optimized method was three
times faster for saxitoxin (Rt 6.5 min) and more sentive than the previously published
method described by Dell’Aversano et al. [173].
Four different product ions were taken into account for the validation and verification of
STX:  one  was  the  quantifier  (Q)  at m/z 282 and other three were qualifiers (q) at
m/z 221 (q1), m/z 204 (q2), m/z 186 (q3). The advantage of the product ion scan method over
previously published SIM or SRM methods [173] is the availability of product ion spectra
for reliable identification of STX and for recognition of false positives. The current OPCW
identification criteria [58] can be met if the intensity of precursor ion is at least 10%. No
precursor ion ([M+H]+) was left in the MS/MS spectrum of the ion trap but four product ions
could be easily monitored and identified. On the other hand, there is no defined number of
diagnostic ions for MS/MS experiments in the WADA criteria, but the abundance of all
diagnostic ions must be greater than 10% of the base peak [57]. Even the least abundant
product ion in our experiments was more than 10% of the base peak. S/N ratios of quantifier
ions were always higher than eighteen to one (≥18:1) even at the concentration level at
5 ng/ml.
Validation was performed using the PSP analogue, gonyautoxin 1 (GTX 1), as the ISTD.
The best alternative for the ISTD is a structural analogue of the analyte, if the isotopically
labeled standard is not available. GTX 1 had a different retention time, different precursor
and  different  product  ions  compared  to  STX.  A  minor  weakness  of  GTX  1  was  that  its
ionization in ESI was inferior to that of STX.
All standards for validation studies were made in a blank algal matrix, which was
extracted as described in study IV. The absence of STX and GTX 1 in the algal matrix of the
blank were ascertained before the validation was carried out. The selectivity of the method
was tested against blank algae samples and purified water during the validation. No effects
were noticed from the early or late eluting compounds during the validation. The retention
times of STX and GTX 1 were 6.47 ± 0.03 min and 4.44 ± 0.01 min, respectively, which
fulfiled the retention time criteria of both WADA and OPCW [57,58]. The validation results
were calculated over the linear concentration ranges from 5 ng/ml to 50 ng/ml (mean
correlation coefficient R2=0.9714, n=9) and from 25 ng/ml to 200 ng/ml (mean correlation
coefficient R2=0.9768, n=9). It was not possible to obtain a linear calibration over the whole
concentration range 5-200 ng/ml because of the bending of the curves that was caused by ion
suppression. Both calibration ranges were accurate and precise according to the calculated
validation results (Table 15) and fell into the FDA recommendations [55]. In addition, LOD
and LOQ were calculated using equations presented in study IV and  were  3  ng/ml  and
11 ng/ml for STX, respectively.
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Table 15 Calculated validation results in an algal matrix spiked with STX standards over the
calibration ranges of 5-50 ng/ml and 25-200 ng/ml (IV).
Standard
conc.
Mean
conc.
SD RSD
(%)
Variance
within
group
Variance
between
groups
Random
error
Systematic
error
Combined
uncertainty
STX 5.0  (LOD) 3.9 0.6 14.5% 30.7% 10.1% 32.3% 3.76% 33%
10.0 (LLOQ) 10.0 0.6 5.8% 8.2% 3.4% 8.9% 0.58% 9%
25.0 26.5 0.6 2. % 7.8% 3.8% 8.7% 0.09% 9%
50.0 49.2 0.3 0.5 % 1.8 % 0.9% 2.0% 0.01% 3%
QC
(25 ng/ml)* 26.9 2.8 10.4% 13.5% 9.1% 16.3% 0.39% 18.8%
STX 25.0 21.7 1.4 6.3 22.6% 11.6% 25.4% 0.29% 25%
50.0 54.3 1.5 2.7 5.2% 1.3% 5.3% 0.05% 7%
100.0 99.3 1.0 1.0 9.0% 5.1% 10.3% 0.01% 11%
200.0 199.7 0.5 0.2 1.8% 1.0% 2.1% 0.00% 9%
*QC runs were performed four times a day; before, in the middle and after every calibration curve (n=12)
The validated HILIC-MS/MS method was tested by quantifying STX in two freeze-dried
dinoflagellate (Alexandrium Ostenfeldii) samples (AOTV-A4/3 and AOTV-B4/6), which
were known to produce STX. MS was tuned again for these analyses with STX solution and
capillary temperature was raised from 300 ºC to 350 ºC. After that, the calibration curves
were linear over the whole range from 5 to 200 ng/ml (R2= 0.999). These linear curves were
then used in the calculation of the quantitative results. Saxitoxin was shown to be present in
these algal samples and the extracted ion chromatogram and the MS/MS spectrum of one
sample is shown in Figure 10. The extracts contained STX at high concentrations
(> 200 ng/ml), so they were given a one in five dilution (1:5). Prior to this dilution the
concentrations of STX in AOTV-A4/3 and AOTV-B4/6 algal samples were determined at
317 ng/ml and 238 ng/ml, whereas after the dilution they were 69 ng/ml and 55 ng/ml,
respectively. Then the actual concentrations of STX in the samples were 345 ng/ml and
275 ng/ml, respectively. A slight ion suppression effect was observed when comparing the
results of diluted and not diluted samples.
The retention time of STX was increased from 6.5 min to 6.7 min during the analysis of
the cultured samples. Salt concentration in the HILIC affects the retention times and this
effect was shown after diluting the samples. In addition, it is recommended to dilute the
samples with the mobile phase and if possible, the reference chemicals should be prepared in
a similar matrix to that used for the actual sample. Another alternative is to spike STX into
the potentially positive sample to verify its presence by increased peak height or area
(method of standard addition). However, the retention times for the HILIC analyses are
comparable within the same sample batch as was the case for our validation study. The
spectral identification is crucial when the method is used for verification purposes because of
the shift in retention time.
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Figure 10 Extracted ion chromatogram and MS/MS spectrum of algal sample AOTV-A4/3 (IV).
5.2.3 GC−MS (SIM) analysis of nitromethane
The GC−MS (SIM) method was optimized and the applicability of two isotopically labeled
ISTD’s was evaluated in study III for the quantification and verification of nitromethane
from in vitro samples.  The  CG  program  and  the  MS  parameters  were  first  optimized  for
nitromethane, D3-labeled nitromethane and 13C-labeled nitromethane. Molecular ions had the
highest intensities and they were selected to SIM analysis. Nitromethane (CH3NO2+·),  D3-
nitromethane (CD3NO2+·) and 13C-labeled nitromethane (13CH3NO2+·) were detected at
m/z 61, m/z 64 and m/z 62, respectively, at the retention time of 2.2 min.
D3-labeled  nitromethane  was  found  to  be  unstable  in  the  studied  solvents,  which  was
probably due to the deuterium−proton exchange. This exchange is known to occur when
slightly acidic nitro group of nitromethane has been deprotonated in the solvent [185].
Nitromethane might then accept the proton from the solvent before reaching the equilibrium
point. The 13C-labeled nitromethane was shown to be stable in the experimental conditions
and therefore it was chosen as the ISTD for the validation.
Validation runs were performed as described in Chapter 4.5 using the following
calibration concentrations: 0.1, 0.3, 1.0, 2.0, 4.0 and 6.0 µg/ml. The ISTD was added into all
samples at the concentration of 3 µg/ml. 1% of non-labeled 12C-nitromethane (~0.03 µg/ml)
was observed in the samples containing ISTD only (method blank) due to the 99% isotopic
purity of 13C-labeled nitromethane standard. However, the signal responses (peak areas) of
12C-nitromethane were 9.0% of the signal from 13C-nitromethane during the validation and
first in vitro sample  batch  which  also  results  from the  [M-1]+· ion of the labeled standard.
The signal response of 12C-nitromethane was 8.7% of the signal from 13C-nitromethane when
using  the  same  ISTD  stock  solution  that  had  been  prepared  one  year  previously.  It  is
therefore recommended that the percentual proportion should always be re-determined
before quantitative measurements and the concurrent percentage be used as a correction
coefficient in concentration calculations of the unknown samples.
Saxitoxin
Q
q1
q2
q3
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The lowest calibration standard concentration was used as the LOQ for this method,
since the linearity was not assessed below 0.1 µg/ml. However, the LOQ and LOD were
calculated using the calibration curves slopes and the extrapolated intersections (see
Supporting Information in study III). The calculated LOD was 0.01 µg/ml and the
concentrations at the same low level could be detected after the use of correction coefficients
due  to  the  increased  signals  from  the  ISTD.  Therefore,  the  LOD  in  the  present  study  was
found to be appropriate and the method is fit for purpose due to the previously found
baseline level of nitromethane for humans [36].
The very high correlation coefficient (mean R2= 0.9996) and appropriate residual plot
(see study III) indicated that the method was linear for the used concentration range. All the
RSD values were 1.5% or under and variances within group and between groups were under
1%, except at the lowest concentration, which confirmed the method to be both accurate and
precise. All the calculated validation parameters are listed in Table 16 and fit the FDA
guidance well [55]. The validated method was applied for analysis of in vitro samples (see
Chapter 5.1.1.3).
Table 16 Calculated validation results for nitromethane analyzed by the HS−GC−MS method (III).
Standard
conc.
(µg/ml)
Mean
conc.
(µg/ml)
Mean
SD
Mean
RSD
(%)
Variance
within
group
Variance
between
groups
Random
error
Systematic
error
Combined
uncertainty
0.1 0.09 0.001 1.5% 2.5% 0.2% 2.63% 15.95% ±16.2%
0.3 0.30 0.003 0.9% 0.9% 0.7% 0.98% 2.96% ±3.2%
1.0 0.94 0.001 0.8% 0.5% 0.0% 0.48% 0.12% ±0.5%
2.0 2.07 0.005 0.2% 0.4% 0.1% 0.37% 0.09% ±0.4%
4.0 4.04 0.006 0.2% 0.2% 0.1% 0.21% 0.04% ±0.2%
6.0 5.96 0.005 0.1% 0.1% 0.1% 0.10% 0.01% ±0.1%
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6. GENERAL DISCUSSION
Conventional in vitro studies were used in the research presented in this thesis for screening
and identification of metabolites of selected toxic and incapacitating chemicals. These
chemicals were sulfur mustard, capsaicinoids and chloropicrin, and the results were
compared with the findings of previous studies with aim of possibly finding new biomarkers
of exposure. Various mass spectrometric methods combined with appropriate
chromatographic separation were used for these studies. Validations of the analytical
methods were conducted to assess the reliability of the known biomarkers of sulfur mustard,
saxitoxin and chloropicrin. Figure 11 shows the overall platform that was used during the
research  for  this  thesis  and  could  be  used  as  a  guideline  for  the  studies  of  new  toxic
chemicals.
Figure 11 Biomarker study platform for toxic chemicals (biological assays are marked in gray, since
they were not included to this thesis).
The results presented in this thesis indicate that at least two different MS analyzers are
needed for screening metabolites and for unequivocal identication when a reference standard
is not available for verification purposes. Moreover, one of the two analyzers should be
capable of accurate mass measurements such as HRMS with an appropriate resolution.
HRMS instruments are commonly coupled with quadrupole, ion trap or orbitrap, to carry out
MS/MS analysis and obtain more detailed structural information [186,187]. Alternatively,
54
LC−NRM would be a suitable choice for exact structural identification [188]. The linear ion
trap together with QqQ used in this study provided adequate data for structural identification
and Q-TOF and Orbitap were used for confirmation. The MS (SIM) analysis is adequate for
identification of small molecular sized chemicals such as nitromethane but using to two
selected ions would have been even more reliable.
Sample preparation and chromatographic separation were found to play a central role in
in vitro sample analysis in this study. Protein precipitation and reversed phase
chromatography were appropriate for studied chemicals. In addition, the liquid-liquid
extraction used for cell culture samples that had been exposed to CAP and DHC were
selective enough to extract novel hydrophilic metabolites excluding a salty backround. The
sample preparation for HS−GC−MS analysis of nitromethane was not needed althought the
optimization of the HS conditions was found to be necessary.
All the MS results for the studied chemicals were compared to previous in vitro and in
vivo findings and many similarities were observed. The previous findings in the case of
sulfur mustard were mainly based on the analysis on animals or human casualties and in the
latter case it was not possible to obtain information about the doses. The known in vivo
reactions were initiated in our in vitro studies and detected for sulfur mustard but the end
products were not found. This finding supports the fact that the toxicological mechanisms of
sulfur mustard are complex and further in vitro studies will be needed to shed light on these.
Such in vitro studies will include different enzyme sources or cell lines to create a more
complete in vitro approach. The oxidation product HDO and three GSH conjugates were
however, detected for the first time in the in vitro samples by LC−MS/MS in this study.
Previous in vitro studies have been performed mainly for CAP [128-129] and not for
DHC, even though the latter is nearly as abundant component in the OC mixtures. Former
studies were mainly focused on elucidating the toxicological mechanisms and not on
biomarker  analysis  after  possible  exposure.  Consequently,  no  metabolites  on  the  skin  or  in
the plasma samples apart from the initial chemicals had been measured. Novel GSH and
glycine conjugates were detected in this study and the latter were found in the extracted
media of the exposed human lung A459 cell culture. The detected glycine conjugate is
interesting  from  a  pepper  spray  exposure  perspective.  Its  use  as  a  possible  biomarker  for
pepper spray exposure should be further evaluated.
The in vitro study on chloropicrin was targeted at the supposed formation of
nitromethane, and this was successfully detected. The formation of nitromethane from
chloropicrin seemed to be dependent on reducing potential e.g. GSH in the in vitro reaction
mixture and support the previous in vivo findings on chloropicrin exposed mice [150,151]. A
validated method therefore could also be used for screening possible human exposures to
chloropicrin.
The optimized and validated fit for purpose verification methods for b-lyase metabolites
and STX in this series of studies focused on fast analysis and reliable identification. Both of
these methods could be applied in verification laboratories. The FDA guidance and the
WADA identification criteria were applied and mainly fulfilled [55,57]. The validated
quantitative methods have usually been applied for QqQ and several transitions followed,
55
however the linear iontrap used was well suited for quantification of STX in a biological
matrix. On the other hand, the current trend will be to move from HPLC separation to
UHPLC, which has already been accomplished and studied in this analytical field
[95,138,177]. This development will produce even faster methods with higher resolutions.
The use of appropriate internal standard for quantifying is essential and will need time and
resources to synthesize, since the most of these biomarker metabolites of toxic and
incapacitating chemicals are not commercially available.
The retention time criteria for the HILIC separation were fulfilled but the samples should
always be from the same batch and must be prepared in exactly the same way. The HILIC
retention mechanism is sensitive to changes and dilution of the sample also shifted the
retention time of STX. Therefore, the availability of full MS/MS spectra and calculated q/Q
ratios for three fragment ions were necessary and sufficient for unequivocal identification of
STX. The WADA identification criteria were slightly confusing in the study of b-lyase
metabolites, because the maximum tolerances for q/Q ratios contained both absolute and
relative values, unlike the EU criteria, which stipulate only relative values and seems more
unequivocal [56]. The current OPCW guideline is based on the EU criteria and therefore
does not require quantitative results [58].
Increasing interest in the future will be focused on the subject of chemical safety and
exposure analysis. In silico methods and miniaturized analysis techniques could be used as a
complement of the metabolism studies [189,190], however the main emphasis will be on
universal sample preparation methods and also sensitive MS analyzers with advanced data-
mining tools.
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7. CONCLUSIONS
The  mass  spectrometric  methods  used  in  the  five  studies  for  this  thesis  were  found  to  be
suitable both for screening and for the identification of metabolites from in vitro samples and
for quantifying target biomarkers. The combination of QqQ, ion trap and HRMS instruments
were inclusive and requisite for the structural identification in those cases for which no
reference chemicals were available.
The conventional in vitro metabolism studies used for sulfur mustard, capsaicinoids and
chloropicrin, yielded new knowledge about the metabolic reactions and produced several
novel metabolites by oxidative reactions and GSH conjugation. However, their clinical
usefulness to serve as biomarkers of exposure in humans requires further studies.
Quantitative fit for purpose analysis methods were optimized and validated for the following
chemicals: saxitoxin, two b-lyase metabolites of sulfur mustard, and nitromethane as a
metabolite of chloropicrin. All methods were found to be accurate and linear and fulfilled the
general identification criteria.
This research is a step towards building up a more comprehensive platform to study
toxic and incapacitating chemicals in vitro and possibly decrease the level of animal testing
in the future.
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